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Stellingen behorende bij het proefschrift 
THE ROLE OF LIPOPOLYSACCHARIDE BINDING 
PROTEIN IN INNATE IMMUNITY IN INFECTED PARTIAL 
THICKNESS BURNS 
van Lars-Uwe Lahoda 
1. Lipopolysaccharide (LBP) is an integral part of the innate immune system which 
defends against Gram-negative infections even in partial thiclmess burns. (dit proef­
schrift) 
2. With regard to innate immunity. LBP-knockout mice profoundly increase intrader­
mal neutrophil chemoattraction in partial thiclmess burns when challenged by 
Gram-negative bacteria. (dit proefschrift) 
3. Adenoviral gene therapy applied in partial thiclmess bums of small rodents is feasi­
ble. (dit proefschrift) 
4. PG-1, an antimicrobial peptide which is part of the innate immune system, is biolo­
gically not deactivated when mixed with a fibrin glue and applied onto an infected 
partial thickness burn, and can therefore be considered for bum wound treatment. 
( dit proefschrift) 
5. Notwithstanding all progress in the treatment of infections, in 2012 the classical 
statement "Ibi pus, ubi evacua" still holds firmly. 
6. Shoot for the moon. Even if you miss, you'll land among the stars. -Les Brown 
7. Nothing is more treacherous then the obvious. 
8. What the superior man seeks· is in himself, what the small man seeks is in others. 
-Confucius 
9. Extreme remedies are very appropriate for extreme diseases. -Hippocrates 
10. Live in New York City once, but leave before it makes you hard; live in Northern 
California once, but leave before it makes you soft. -Mary Schmich, Baz Luhrmann 
- Everybody's Free {Tb Wear Sunscreen) 
11. Most researchers use statistics the way a drunkard uses a lamp-post - more for sup­
port than illumination. -Winifred Castle 
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1.1. General Introduction 
1.1.1. Fire and the human body 
Fire is one of the oldest achievements of mankind. It has brought warmth, light and 
enabled to process materials. It has also made cooking possible and therefore aided in 
the preparation as well as preservation of food. It can be stated that fire has significantly 
contributed to major evolutionary steps. Along with lots of benefits, there was always 
the danger of an accident; the destructive nature of fire and the danger of being burnt 
are imminent since ancient times. Bums historically originate from social, environmental 
and industrial causes. Today, at least in the western world, they are largely outnumbered 
by accidents originating from means of transportation as well as warfare or catastrophes. 
Our skin has many different functions: it protects us and warns us if we are getting too 
close to a heat source. Intact skin represents a barrier. It protects mechanically, thermally 
and chemically, it shields (to some extent) against radiation and prevents bacterial in­
vasion. Skin regenerates by itself throughout life, it even lubricates itself and contains 
several different types of glands and appendices such as hair and nails. Next to these 
functions this organ plays an important immunologic role by balancing fluids, proteins 
and electrolytes, it supports renal function ('perspiratio insensibilis') and is crucial for ther­
moregulation. Endocrine capacity leads to Vitamin D processing and last but not least, 
skin represents somatovisceral sensibility, a fact that not only the vision-impaired ac­
knowledge and know too well. 
Heat is capable of harming the human body in several ways, locally, and systemically. 
High temperature triggers pain and alerts the organism, denaturizes proteins and as a 
consequence destroys the intact layers of the protective skin in varying depth, depending 
on temperature and time of exposure. Bums are graded in I, IIA and IIB, III and IV degrees 
of bums, with I being defined as erythema and IIA a superficial 2nd degree of burn with 
blister formation due to a destruction of the epidermis, damage which will restore within 
2 weeks' time. IIB stands for a 'deep' intradermal bum and is characterized by a viable 
wound bottom, from which the wound may heal, and a III degree of burn represents a full 
thickness, dermal bum, where all dermal structures have been destroyed and healing can 
only occur form the wound edges and deeper tissues if left untreated. In addition to this 
classic system, a 4th degree was added over time and meaning an even deeper destruction 
and exposure of functional tissues such as muscle, tendons and bone. 
Superficial bums (I and IIA) heal without scars if uninfected, deeper bums bear an 'es­
char' (a layer of dead dermal tissue) of varying thickness. As such, the deeper the burn 
wound reaches, the longer and more challenging it gets for the body to deal with and 
11 
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Chapter 1 ultimately heal in a scar. Untreated deeper burn wounds are to be avoided due to un­favorable outcomes, such as poor aesthetics as well as poor function. This may lead to unstable coverage of the underlying tissue resulting in impairing contractures. 
1.1.2. Burn wound infections Immediately after the injury, burn wounds are initially sterile. Sterile wound coverage and dressing changes and immediate treatment help prevent further infection. Unfortu­nately, over time the transient Gram-positive bacteria naturally colonizing the surround­ing undamaged skin, as well as Gram-negative bacteria (normally not found on healthy and intact skin) invade the burn wound if untreated. The longer the skin is not capable of completely healing and restoring its protective layers, the higher the bacterial and sometimes fungal numbers found. Vice versa: the more bacteria and/ or fungi are present in burns, the more complicated, less successful and more time-consuming the healing process becomes, and the weaker the host gets. Infected burn wounds are a source of high morbidity and mortality (1). In the US the lethality arising from burns in males is roughly 4%, whereas in females it is 5.5% (2). Deaths related to burns increase with advancing age, burn size and the presence of an inhalation injury (3). In 2010, 450,000 medical treatments resulting from burns led to 45,000 hospitalizations and on average 5,000 extensive surgical reconstructions and in­terventions (3). The top complications following burns recorded in 126,000 complications according to the report of the American Burn Association are in descending order: pneu­monia, urinary tract infection, wound infection, respiratory failure, and septicemia. Cur­rently, sepsis mortality originating from either burn, trauma or other conditions leading to an intensive care treatment, reaches numbers between 37% on general intensive care units and 65% on burn units (4). Over time, bacteria developing multi-resistance have become an increasing problem in such surroundings. Burn wound infections are possible sources of sepsis, which pose serious threats to patients, and represent major challenges to the treating physician. Gram-negative bacteria are challenging to treat and eradicate (5) due to a weakened host that lacks competing, opportunistic Gram-positive bacteria. They favor nutritious wound fluids and moist dressings needed in burn care. Due to their nature, Gram-negative bac­teria form 'biofilms', meaning they stick to surfaces and surround themselves with a mechanically protecting protein barrier, making antibiotics hard to penetrate. Routinely, antibiograms are taken repetitively and frequently show rapid changes in antibiotic sen­sitivity and -resistance, leading to challenging and difficult therapies (6). 12 
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1.1.3. Lipopolysaccharide binding protein (LBP) as part of the innate 
immune system 
Next to the mechanical barrier of the skin acting as a shield, the host has limited options 
to address the problem of invading bacteria in case this shield is breached. It is most 
important for the immune system to generate a quick response to the threat. A key com­
ponent of the innate immune system dealing with Gram-negative bacteria is lipopolysac­
charide binding protein (LBP). LBP is a glycoprotein, synthesized as a SO kD polypeptide 
at numerous sites of the organism such as the lung, the liver, the gastrointestinal tract, 
and the skin. It is present in serum at a concentration of 2-4 µ,g/ml and rises as an acute 
phase protein in case of infection (7). LBP potentiates bacterial killing mediated by bacte­
rial permeability increasing protein (BPI) (8) by 10,000-fold, it disaggregates lipopolysac­
charide (LPS), enhances the binding of LPS to the cellular membrane via the (soluble and 
membrane-bound) CD-14 complex (9), and binds to and therefore activates Toll-like recep­
tor 4 (TIR-4) (10). This protein also potentiates the production of tumor-necrosis-factor 
a (TNF-a) by macrophages, and according to several investigators, it protects mice from 
lethal bacterial peritonitis in a dose-dependent manner (11-13). Furthermore, its mes­
senger RNA-levels rise in abdominal sepsis, indicating a key role of LBP in Gram-negative 
sepsis (13). Lipopolysaccharide (LPS) of Gram-negative bacteria acts as an inducer of the 
innate immune system via TLR4 and myeloid differentiation factor 2 (MD-2) (14, 15). LBP 
and CD-14 seem to play a key role in initiating the pro-inflammatory cytokine production 
following LPS- TLR-4 and MD-2 activation (16). LBP plays therefore a key role in physi­
ologic and pathophysiologic Gram-negative infection (17). 
1.1.4. Antimicrobial Peptides 
In recent years, no new classes of antibiotics have been reported while, as stated before, 
multi-resistant bacteria more and more pose a serious problem in patient care. As a conse­
quence, researchers turned to evolutionarily ancient weapons, such as 'antimicrobial pep­
tides' (AMPs). Their widespread distribution throughout the animal and plant kingdoms 
suggests, that antimicrobial peptides have served a fundamental role in the successful 
evolution of complex multicellular organisms (18). Animals and plants possess these po­
tent, broad-spectrum antimicrobial peptides which are used to fend offinvading microbes, 
including bacteria, viruses, fungi and protozoa (18). AMPs are naturally occurring cationic 
peptide molecules with broad antimicrobial activity. They consist of a hydrophobic and 
hydrophilic 3-dimensional structure enabling binding and integrating into cellular mem­
branes (19). By binding, subsequently 'pores' are formed, resulting in cellular death (20). 
There are two major families known to be important in the skin of mammals, namely 
cathelicidins and defensins (21). The group most widely studied are the cathelicidins, Pro-
13 
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Chapter 1 tegrin-1 {PGI, PG-1) being one of the major representatives {22, 23).In mammals however, these classes of peptide molecules are encoded by several varying genes {24). Interest­ingly, they are expressed on epithelial surfaces, produced by immune-competent cells, and are therefore suggested to be part of the innate immune system {25). It is believed that these naturally occurring peptide molecules are active against bacteria, fungi and enveloped viruses, and therefore play a crucial role in mounting an innate immune re­sponse to injury and microbial insult {26, 27). Furthermore, they are not only profoundly responsible for antimicrobial activity but also act as signaling molecules activating host cell processes involved in immune defense and tissue repair {21). Recent articles more specifically report that the function of these peptides is not only in direct defense of invading bacteria, but rather do they play a complex role in the immune response not only restricted to the innate immune system {28). Further evidence suggests that they are acting in a concentration-dependent manner {29), and they are described to play a role in infectious skin diseases, dermatitis conditions and several other diseases such as Crohn, s {30-32). AMPs are thought to play a role as mediators of inflammation, and to influence cell proliferation and wound healing as well as cytoki.ne / chemokine produc­tion and chemo attraction {33, 34). Given the potent and broad-spectrum activity of these naturally occurring antimicrobial peptides, which can also be called host defense peptides {HDPs), the idea of using them as novel therapeutics supporting and maybe enhancing the traditional antibiotic spec­trums, is not far-fetched {26, 35, 36). There is a definitive need for the development of new classes of antimicrobial agents, especially with regards to problematic wounds as represented by burns. Summarizing, the clinical dilemma of infected burn injuries presents itself with a wide variety of problems. It is beyond any doubt that burns per se represent a problematic in­jury to the body. Burn wound infection is a source of high morbidity and mortality. More specifically, within infections as such, Gram-negative ones pose a more serious problem than Gram-positives. In recent years it was noted that multiresistant bacteria are on the rise and taken responsible for prolonged hospital stays, higher health care cost, and in­creased mortality, particularly, when initial antibiotic therapy does not provide coverage of the causative pathogen {37). Current lmowledge arising from in vivo experiments with regards to LBP is drawn from abdominal sepsis models, whereas basic science and research models mostly investigate LBP-LPS interaction in vitro. To date, little is lmown about the effect of living Gram-nega­tive bacteria on the immune system in partial thiclmess burns in vivo. Still, questions like: cc • • •  do increased LBP levels in burn wounds decrease numbers of Gram­negative bacteria locally?", cc • •  . is there possibly a systemic consequence and which?" and 14 
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ultimately: " .. . does LBP really play an essential role in the innate immune system fight­
ing against invading Gram-negative bacteria in burns?" need to be answered. 
1.2. Aim of the thesis 
Based upon the knowledge summarized above, the objective of this research was to gain 
more insight into the role of the innate immune system in infected bum wounds with 
special regards to LBP-LPS interaction. To date, the interaction of living Gram-negative 
bacteria in a per se problematic deep partial thickness bum wound with the innate im­
mune system is rather unclear. Therefore following aims are defined: 
1) To develop an in vivo, deep partial thickness (IIB) burn wound model in mice and apply 
this to both a new IBP-knockout mouse model and its corresponding wild type control; 
2) To gain more insight into the ability of LBP to reduce the number of living, multiresistant, 
Gram-negative bacteria in deep partial thickness (IIB) burn wounds with special regards 
to innate immunity; 
3) To apply an adenoviral construct encoding LBP as a tool to study whether this intradermal 
adenoviral gene delivery system represents a feasible therapeutic approach to bacterial 
infected burns; 
4) To test the ability of a new class of antimicrobial agents (AMPs) capable of reducing the 
number of bacteria in our deep partial thickness burn wound model. 
1.3. Outline of this thesis 
The first set of experiments in Chapter 2 introduces a deep partial thickness mouse bum 
model in a strain of C57BL-6 wild types compared to their LBP knockout, weight- and 
age-matched siblings. In this model, an adenoviral construct containing the genetic in­
formation for rat-LBP was used as a vector to deliver LBP intradermally at the site of bum 
injury. To be able to compare its effect, and following a series of in vitro tests, the viral 
construct was injected in LBP-deficient mice as well as wild-types, the virus was applied 
following a series of in vitro tests. The injection site was the living bottom of the partial 
thickness bum wound allowing insight into innate immune mechanisms by enhancing 
LBP expression locally and potentially confirming its importance in innate immunity. In 




a defined, multiresistant, living number of Pseudomonas aeruginosa bacteria, to mimic 
Gram-negative infection of a serious kind, feared in patient bum care. This set up proved 
the feasibility of gene therapy in our model. 
Chapter 3 makes use of the developed model described in chapter 2. Aiming to identify 
the molecular changes induced by bum and infection in either mouse strain, commercial­
ly available gene-chip arrays were used to analyze intradermally extracted, pooled RNA/ 
cDNA. Since greatly different bacterial numbers were found on the skin of our two mouse 
strains, we sought to determine possible altered gene expression patterns explaining 
such findings. Striking differences over a variety of genes were found and considered sig­
nificant, when up- or down regulated at least 2-times compared to the standard in either 
mouse population. The gene which was found to be the most up-regulated, is known 
to be a chemo attractant of neutrophils, called growth-related oncogene-1 {GR0-1) and 
represents a link to the innate immune system as such. GR0-1, a CXC-chemokine, can 
be regarded as the murine analogue to human interleukin-8 {IL-8). This introduces the 
neutrophil as a possible key component in the findings of different immunity between 
the 2 strains. 
In order to decipher more clearly the role of the neutrophil and other leukocyte sub­
sets in our LBP-knockout animal model over a longer period of time, systemic and topic 
tests were conducted in either colony. Chapter 4 describes the results of peripheral blood 
analyses of the knockout compared to C57BL-6 wild type mice at several different time 
points following bum challenge and infection. These experiments were designed to find 
out, whether an altered local or systemic concentration of neutrophils was the case at 
several time points. Possibly, the animals had a different white blood pool composition 
of leukocyte subsets to start off with, explaining profound changes in immune response 
when challenged. Potentially this would also involve pro- and anti-inflammatory cyto­
kine expression which was also focused on in this chapter. In all of our immunologic and 
molecular biologic tests conducted in this chapter, LBP-knockout and wild-type animals 
proved to be different. 
Finally, a new class of naturally occurring, antimicrobial peptide molecules playing a role 
in innate immunity was introduced into our bum wound infection model {chapter 5). 
These peptides have drawn attention due to the fact of their vast variety of antimicrobial 
activity and their ancient origin (paragraph 1.1.4). In an attempt to use a designer peptide 
{Protegrin-1, PG-1) in our bum model we conducted a series of in vitro and in vivo tests 
to proof its efficacy. Following, this peptides was introduced into our model aiming at 
answering the question whether it would be de-activated by mixing it with fibrin glue. A 
mixture of PG-1 and fibrin glue would consequently represent a new topical, antibacterial 
agent supporting bum wound treatment in case of infection, a great clinical challenge. 
The findings of the preceding chapters and the future perspectives related to these find­
ings are discussed in chapter 6. 
16 
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Background: Infections occurring in burns are responsible for high mortality and morbidity. Gram-neg­ative infections are of great concern, but little is known about the complex mechanisms of the innate immune system responsible for eliminating bacteria in partial thickness burn wounds. We aimed at shedding more light onto the role of lipopolysaccharide binding protein (LBP) in clearing bacteria and the resulting innate immune responses in a rodent partial thickness burn model. For this purpose, we used IBP-knockout mice and LBP-rescue experiments initiated by living, multidrugresistant Pseudomonas aerugi.nosa as the source of lipopolysaccharide (LPS). 
Methods: A partial thickness (type IIB) burn wound model was designed in LBP-knockout mice and their wild type control strain (C57BL/6). We developed a rat-LBP encoding adenoviral construct and used adenoviral (3-galactosidase ((3-gal) as control. In vivo, female C57BL/6 and corresponding, homozygous IBP-knockout mice received a standardized burn, where appropriate followed by topical adenoviral injection encoding rat-LBP or control (3-gal. Three days postburn, 1xl05multiresistant Pseudomonas aerugi.nosa were topically seeded and covered by occlusive dressings. Seventy-two hours later, the skin was harvested for quantitative bacterial counts. 
Results: 
In vitro, the efficacy of the adenoviral constructs was confirmed by light microscopy, Xgal staining ((3-gal expression) and Western blotting (LBP expression) using mouse fi­broblasts. In vivo, positive Xgal staining in burned mouse skin was achieved indicating successful gene transfer. Bacterial counts on the skin of mice subjected to burn and infec­tion did not differ between LBPko mice and wt controls. Both, in wild-type animals and in LBPko animals, application of the LBP-producing virus resulted in 4,9-fold respectively 44-fold lower bacterial counts compared to the counts in (3-gal transfected mice. 
Conclusion: In a standardized burn wound model, restoring LBP in IBP-knockout animals as well as overexpression of LBP in wild type mice, resulted in improved local immunity. LBP thus plays an important role in topical innate immune response to Gram-negative bacteria. Adenoviral over-expression of IBP has a protective effect against local wound infection and may therefore be considered as a future therapeutic approach for Gram-negative burn wound infections. 
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Materials and Methods 
Animals 
LBP knockout mice were a gift from Dr. Douglas Golenbock (Boston University School of 
Medicine) (20). The animals had been backcrossed at least 12 times into their C57BL/6 
background prior to use and were previously shown to be homozygous. All experiments 
were performed in accordance with National Institute of Health guidelines for the use of 
laboratory animals and approval was obtained from the University of Michigan Animal 
Care and Use Committee. Mice were kept in specific pathogen-free environment under a 
12-hour light cycle, and fed rodent chow and water ad libidum in micro-isolator contain­
ments. For all our experiments, we used 12-14 weeks old, female, age/weight-matched 
mice. C57BL/6 wild-type animals were purchased from Harlan (Harlan, Indianapolis, IN), 
and allowed at least 5 days for acclimatization prior to use in experiments. 
Bacteria 
A silver sulfadiazine-resistant strain of Pseudomonas aeruginosa (lot-no. 26-2844) was pre­
viously isolated from a human burn patient at University of Michigan burn ICU (21). This 
bacterium was transferred into 10 ml of trypticase soy broth (Becton Dickinson, Franklin 
Lakes, NJ) and shaken at 275 rpm overnight at 37° C. The next day, an aliquot of bacteria 
was mixed with 10 ml of broth and shaken for another 2.5 hours for bacteria to reach 
semi-log growth phase. After spinning and washing with chilled phosphate buffered sa­
line (PBS, pH 7.3), a suspension of 1x105 bacteria per 100µ1 in PBS was made. 
Adenoviral constructs Ad-LBP: 
Following the methods described by Aoki et al. (22), the University of Michigan Gene Vec­
tor Core produced an Ads adenovirus with a dl309 backbone containing the information 
for rat-LBP. Briefly, the secretory tag sequence of the plasminogen activator inhibitor type 
1 gene was inserted one amino acid upstream of the histidine tag from the previously 
constructed transfer vector pBlueBacHis2c, using polymerase chain reaction (PCR).The 
PCR product was then cut with Mfe/HindIII and subsequently cloned into an adenoviral 
shuttle vector (pACCMVplmpl-SSP containing a CMV promoter). Next, a Xho/HindIII seg­
ment of the vector was replaced with a Xho/HindIII fragment (2.45kb) of rat LBP gene 
from pBlueBacHis2c(15) (see Figure l a}. 
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Figure 1 b: Control AdS-adenoviral construct expressing p-galactosidase. 
This virus is used as a control adenoviral vector and expresses �-galactosidase (Ad�-gal). When success­
fully transfected into cells, b-gal activity can be detected as blue when counter-stained with Xgal stain­
ing. The construct was made of a similar Ads-virus with a dl309 backbone as the LBP-producing virus. 
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Chapter 2 Ad-f3gal: The control adenovirus construct expressing �-galactosidase, was made by the Univer­sity of Michigan Gene Vector Core as well, according to the methods described by Gerard and Meidell {23) (see Figure lb). 
In vitro adenovi ra l  gene transfection  experiments NIH/3T3 mouse fibroblasts were purchased from ATCC {ATCC, Manassas, VA, No: CRL-1658) and grown in Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjust­ed to contain 1 .5 g/L sodium bicarbonate and 4.5 g/L glucose, and10% bovine calf serum, at 37° C. The adenoviral transfection medium was identical to the growth medium with the exception of the use of 3% bovine calf serum to increase the uptake of the virus. For the in vitro transfection experiments, multiplicities of infections {MOI) of 10, 100, 1 ,000 and 10,000 were used. Adenoviral transfection was performed in 12 well Costar® plates. 5xl05 cells/well were seeded into the wells, allowed to rest for 24 hrs, then incubated with virus of the desired MOI for 2 days in transf ection medium. The f3-gal-construct was used to confirm successful transfection (see Xgal staining, Figure 2) , using light microscopy evaluation. After 2 days of virus incubation, the supernatants were harvested and the cells were lysed and subjected to Western blotting (Figure 2}. 
Xga l  expression ana lysis i n  ce l l  cu ltu res NIH/3T3 fibroblasts were harvested with Trypsin-EDTA {GIBCO/Invitrogen Life Sciences, Carlsbad, CA), spun, washed and mixed with Xgal fixation buffer {2.7 ml of 37% formal­dehyde {Fisher Scientific, Fair Lawn, NJ), 0.4 ml 25% glutaraldehyde {Fisher Scientific, Fair Lawn, NJ), filled to 50 ml with PBS (pH 7.3)) until a total volume of 50 ml was reached for 5 min on ice, followed by rinsing with PBS three times. The resulting cell pellet was 
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Figure 2: Brightfield microscopic view of two repre­
sentative 3T3-NIH mouse fibroblasts showing posi­
tive Xgal staining. 
An example of two viable NIH-3T3 mouse fibroblasts 
in culture, after successfully being transfected with 
the Ad�-gal virus 2 days following adenoviral trans­
fection. By Xgal staining these cells appear blue when 
�-galactosidase is being produced. The multiplicity of 
infection (MOI) was 100, the picture is taken at 400x 
magnification. 
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mixed with Xgal staining solution (1 .0 ml X-gal solution stock (25 mg/ml) 50 µl MgC12 , 
41mg potassium-ferricyanide, 53mg potassium-ferrocyanide, mixed with PBS (pH 7.3) to 
a total volume of 25 ml) and placed in an incubator at 37° C overnight. Next, cells were 
washed, the cell solution was then mounted onto object slides and subjected to micro­
scopic analysis. 
Xgal staining of mouse tissue skin samples 
OCT frozen skin samples were cut in 5-micron sections, transferred onto standard slides 
and processed by soaking in 10% formaldehyde (Fisher Scientific) overnight, followed 
by dehydration in 70% ethanol, embedding in paraffin and subsequent Xgal staining, 
followed by counterstaining with Eosin and Nuclear Fast Red. Samples were soaked in 
fixation buffer (4% formaldehyde, 25% glutaraldehyde (Fisher Scientific), 100 µl 10% 
Tween-20, Lac-Z-rinse (50 ml PBS-Tween (pH 7.3), 1 m MgC12 , 100 µl Tween-20, 448ml 
water) (InvivoGen)) for 5 minutes at room temperature. The slides were rinsed twice 
with lxPBS-Tween and placed into Lac-Z-rinse for 10 minutes. Subsequently, 200µ1 of 
staining solution (200µ1 0.4 M K-ferricyanide solution (325 mg potassium ferricyanide 
powder (KleCN6) in 5 ml lxPBS (pH 7.3) and 200µ1 of 0.4-M K-ferrocyanide (potassium 
ferrocyanide (Kle(CN)/3H20) in 5ml lxPBS (pH 7.3) with 10 mg X-gal 0.25ml (40mg/ml)) 
was added onto the specimens and incubated overnight (12-18 hrs). The next morning, 
the specimens were rinsed with lxPBS-Tween, soaked for 5 minutes in PBS-Tween and 
counter-stained with Nuclear Fast Red and Eosin). 
Western blot analysis of LBP production in cell cultures 
Cells transfected in vitro by the adenoviral constructs and their corresponding superna­
tants were harvested, and the cells were mechanically lysed. Cell extracts and superna­
tants were separated by SDS-PAGE using a 10-12.5% gel under reducing condition using 
the method of Laemmli (24). The protein transfer was performed electrophoretically by 
the method of Towbin et al. (25) to a nitrocellulose membrane (Schleicher and Schuell, 
Keene, NH). The membrane was probed with either mouse monoclonal anti-HIS antibody 
(Invitrogen Life Sciences, Carlsbad, CA; No. R93025) or mouse monoclonal anti-Xpress 
antibody (Invitrogen, No. R91025), followed by a horseradish peroxidase-linked goat anti­
mouse IgG antibody (Schleicher and Schnell). Detection was carried out with the Western 
Lightning (Western Lightning kit, PerkinElmer Life Sciences, Boston, MA) blotting kit ac­
cording to the manufacturer's guidelines, normalized to GAPDH as a housekeeping gene. 





Mouse burn model For each experiment, eight female C57BL/6 mice (Harlan, Indianapolis, IN) and eight age and weight-matched female LBP knockout mice were clipped at their dorsum under gen­eral anesthesia. Anesthesia was given by intraperitoneally (ip) injection of 60-80 mg/kg Ketaset® (Ketamine HCl, lO0mg/ml, Fort Dodge, Fort Dodge, IO) and 15 mg/kg AnaSed® (Xylazine 20mg/ml, Lloyd Laboratories, Shenandoah, IO). The animals were then depil­ated with a depilatory lotion (Nair®, Carter Products, New York, NY) and placed in a mold exposing 25% of their dorsum in a hot water bath by partially submerging (60° C for 10s), to create a partial thickness burn wound. The bum wound size was deter­mined by the Meeh formula (26). Immediately postbum the skin was dried and animals resuscitated with ip saline. All animals received an intra-/ subdermal injection of either the b-gal (control group) or rat-LBP-expressing adenovirus per group. We injected 1010 plaque-forming units (pfu) in 100 µl solution of both constructs under sterile conditions, pfus were determined by plaque assay prior to the experiment. For postoperative analge­sia, buprenorphine was injected subcutaneously every 6-8 hours for 2 days (Buprenex®, Reckitt & Colman, Richmond, VA). The adenoviral injection site was marked on the skin and covered with a sterile dressing (Telfa® (Non-adherent dressing, Kendall, Mansfield, MA), Tegaderm® (3M Health Care, St.Paul, MN) for occlusive dressing and Flex-Wrap® (Kendall, Mansfield, MA) to prevent animals from removing their dressings). Seventy-two hours post-burn, we performed a dressing-change and applied 105Silvadene®-resistant 
Pseudomonas aeruginosa topically onto the site of bum and viral treatment, followed by another occlusive dressing. Seventy-two hours after wound challenge with bacteria, the animals were euthanized for tissue harvest. 
Pseudomonas colony analysis in skin samples Skin was harvested under sterile conditions, weighed and homogenized in saline on ice. Homogenates were plated in serial dilutions in triplicates (102, 104, 106) on 5% sheep­blood agar plates. The following day, the Pseudomonas colonies were counted in a blinded fashion and standardized per g/skin, presented as calculated mean of plates, done in triplicates. Pseudomonas growth was revealed by morphology, odor and colony aspect. 
Statistica l ana lysis Statistical analysis was performed by using StatView software (SAS Institute, Cary, NC). Data shown express mean value ± 1 SE (standard error), comparison was performed us­ing two-tailed Student's t test. 
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Results 
Adenoviral transfection in fibroblasts In order to proof the efficacy of transfection and protein production of the adenoviral constructs, both were tested in mouse fibroblasts. In our in vitro experiments, light-mi­croscope evaluations revealed an average (3-gal transfection rate (blue staining of fibro­blasts) of approximately 30% (data not shown) . As demonstrated in Figure 2, positive (3-gal transfection turned viable cells blue. As for the LBP-producing virus, Western blot analysis confirmed successful expression of the protein LBP (Figure 3) which showed up at the expected size of LBP (58-60 kDa). A previously produced LBP was run in the same gel with the fibroblast supernatants to confirm LBP production. In order to find a virus concentration - production response relation, different MOis were tested and LBP expres­sion was found to follow increasing MOI as shown in Figure 3. 
Adenoviral transfection in vivo Based on the successful in vitro transfection of both adenovirus constructs, further in 
vivo testing was done by applying them to the burn wound model. Examination of burn wounds 6 days following burn injury and immediate treatment with adenovirus, dem­onstrated that the burn wound is capable of expressing the transgene, as seen in Figure 
4. Positively (3-gal transfected intradermal cells showed blue staining, similar to what is seen in culture, in contrast to non-infected cells. Adenoviral encoded protein expression could be seen intra- as well as subdermally. 
LBP I.BP &-gal 
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Figure 3: Western blot analysis of proteins derived from lysates of cells transfected with either ad­
enovirus producing rat-LBP or p-gal. 
Adenovirus driven LBP protein production was positively identified by detection of a protein band at 58-
60 kDa with similar identity as the reference LBP. 
Molecular weight ladder left and right enabled identification, left band (LBP 1:50), shows the reference 
LBP-protein band. The two following dark bands suggest positive protein production at the expected size 
of 58-60 kDa with MOis of 100 respectively 1 ,000. The protein products of the Adj3-gal virus (j3-gal MOI 





Figure 4: Rodent skin sample 2 days after in­
traderm.al adenoviral injection. 
Positive transfecti.on is visible intra- and sub­
dermally by blue staining (Xgal stain for 
B-galactosidase, counterstained with nuclear 
fast red). The virus concentration administered 
was 1.1010 particle-forming units (pfus) in 100 
µJ. 
Arrows 'N point to subdermally stained cells, 
arrows 'B' point to intradermally stained cells 
(basal layer). The picture is taken at 200x mag­
nifl.cation 
Bu rn model and bacteria l cha l lenge After the development of  the burn wound model and the proof that the adenoviral con­structs expressed either LBP or B-gal, a bacterial challenge study with living, multiresis­tant Pseudomonas aeruginosa was performed. All but one animal (6,3%, n= 1/16) survived the experimental course. In order to focus on the effect of these bacterial colonies only, we tried to prevent cross contamination. Therefore, to keep the wound environment standardized, we designed the occlusive dressing as described before. Three days following burn and infection with the multiresistant Pseudomonas, less bac­teria were found on the skin of wild-type animals compared to the numbers on the skin LBPko mice, although this was not statistically significant (Figure 5). In order to test our hypothesis that LBP would be beneficial in clearing bacteria, both adenovirus constructs were injected into the living, regenerating wound ground of the wild type C57BL/6 mice. Another 72 hours after infliction of the defined burn wound followed by infection, the bacterial numbers were compared, as can be seen in Figure 6. The numbers were statistically significantly lower on the LBP-transgene skin by 44-fold compared to the numbers on the skin of the B-gal transfected mice. The same approach was repeated by injecting either viral construct into the skin of LBP-knockouts, followed by standardized infection and quantitative counts (Figure 7). In knockouts where the LBP encoding virus had been injected and thus LBP has been re­stored, we found that Pseudomonas numbers were lowered by 4.9-fold, than the numbers found upon administration of the control virus. This difference was statistically signifi­cant (p < 0.03). 
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Figure 5: Comparison of Pseudomonas bacterial numbers on skin of I.BP-knockout animals versus wild 
types following bum and defined infection. 
Three days following burn wound and infection with lxl05 Pseudomonas aeruginosa bacteria, quantita­
tive bacterial counts were performed, comparing knockout animals to wild-types. No statistical signifi­
cance was found using Student's t-test, the bacterial numbers were comparable. (n=8 animals / group, 







Ad-bgal / CS7 wr Ad-LBP / cs? wr 
Figure 6: Pseudomonas bacterial numbers on wild type mice, comparing Ad-bgal versus Ad-I.BP treat­
ment. 
Either adenovirus was injected intradermally into wild type mice (C57 WT) immediately after the burn 
was covered by sterile dressing, three days later the animals were infected by topical application of lxl 05 
bacteria. Another three days later, quantitative bacterial counts of treated and infected dermis were per­
formed. The Ad-LBP virus reduced the Pseudomonas numbers by 44-fold on wild type skin. 
Bars represent the mean values of 8 mice, with + /- 1 SE. Asterisk sign indicates significance (p < 0.03) 
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Ad-bgal / LBPko Ad-LBP / LBPko 
Figure 7: Pseudomonas bacterial numbers on LBP-knockout mouse skin, comparing Ad-bgal treatment 
versus Ad-I.BP treatment. 
After inflicting the burn wound, the IBP-knockout mice were injected with adenoviral construct and 
covered by sterile wound dressings for 72 hours, then got infected by lxl05 Pseudomonas aeruginosa 
bacteria, covered again and another 72 hours later the skin was harvested. 
'Restoring' LBP by means of the adenoviral construct (Ad-LBP / LBPko) led to a statistically significant 
reduction of bacterial numbers by 4.9-fold, when compared to the control virus. Asterisk sign indicates 
significance with p < 0.03 (n=8 animals /group, + /- 1 SE) 
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Discussion 
Burn wound infections remain common despite the high standard of care on burn in­
tensive care units. Depending on burn depth and extent, sepsis emerging from wound 
infection following burns remains a major cause of mortality and morbidity (27), making 
especially Gram-negative infections troublesome. By establishing a standardized, partial 
thickness burn wound model in rodents, we could test our hypothesis that local LBP ex­
pression plays an important role in the innate immune response towards Gram-negative 
bacteria. Using wild type and LBP-knockout mice, as well as an adenoviral gene delivery 
system encoding LBP, we showed that genetic ablation of LBP expression per se did not 
affect bacterial counts in the model used. In addition, we could demonstrate a significant 
decrease in topical bacterial numbers in mice treated with the LBP-encoding adenovi­
rus, both in wild type and in LBP-knockout mice. This adenoviral over-expression of LBP 
might be considered as a future therapeutic approach to diminish bacterial load in critical 
wounds, such as burns. 
In Gram-negative bacterial infections as such, lipopolysaccharide-binding protein (LBP) as 
part of the innate immune system, is considered to play a key role (28-30). The generally 
accepted dogma states that LPS, as a major component of the outer cell wall of Gram-neg­
ative bacteria, binds to LBP, further initiating an immune response, but the importance of 
LBP in partial thickness burns remains rather unclear (19). Consequently, we developed 
a burn wound model, enabling us to focus on LBP and innate immunity, by means of an 
LBP-knockout mouse colony, for which we adapted exposure time and mold design previ­
ously found useful in our roughly 10-times bigger rat bum-wound model (19). 
We postulated that LBP is an important component of local wound defense against bacte­
rial infection in a rodent burn wound model, and that local over-expression of LBP within 
the wound site may be therapeutically advantageous. With regard to our LBP-knockout 
mouse colony being unable to produce LBP, complex immunologic mechanisms involv­
ing Gram-negative infections are expected to be profoundly different when compared 
to wild-type animals. In our case however, we did not observe a deleterious effect on 
bacterial clearance of knockout animals lacking LBP. It is accepted, that LBP facilitates 
the binding of LPS to CD14, a membrane-bound anchor protein without transmembrane 
components found on monocytes, macrophages and neutrophils. Alternatively, LBP de­
livers LPS to soluble CD14 (sCD14) to form LPS-sCD14 complexes that may activate a 
much larger variety of cell types, including CD14-negative cells such as endothelial cells 
(31, 32). The animals used in our experiments, however, were incapable of producing a 





in our case Pseudomonas, possibly existed, since we did not find differences in bacterial 
numbers on LBP-competent (wt) and incompetent (LBPko) mice. Although LBP was shown 
not to be required in vivo to clear LPS (delivered through Gram-negative infections), in an 
animal study with LBP-deficient mice (33), it was shown to be necessary for the rapid in­
duction of an inflammatory response by small amounts of LPS or Gram-negative bacteria. 
LBP and CD14 together represent the major pathway by which cells recognize low con­
centrations of LPS (34), presenting the LPS-LBP binding signal to members of the Toll-like 
receptor family (TLRs), mediating it to intracellular compartments (35, 36). Specifically, 
both TIR2 and TIR4 are highly expressed by cells in response to LPS-exposition, such as 
macrophages and monocytes (15, 37, 38), but only TIR4 is accepted as an LPS signaling 
receptor (39). Many downstream activators are triggered by the LPS signaling in mono­
cytes, for instance rapid tyrosine phosphorylation of proteins, such as the src tyrosine 
kinase family members (40). LBP-LPS binding stimulates macrophages and monocytes to 
produce inflammatory proteins such as TNFa, IL-6 or IL-1 (40, 41). Since no functioning 
LBP-protein was produced in the LBPko mice used in our experiments, one can speculate, 
that there were possible compensatory mechanisms enabling burned and infected LBPko 
mice to demonstrate the same bacterial clearance as their corresponding wild types. 
The knockout animal concept is per se an investigatory tool, and its resulting information 
can be expanded by restoring the gene which is initially knocked-out, for instance using 
gene-therapy. Currently available vectors for introduction of transgene encoding infor­
mation include retroviruses, liposomes, plasmids, gene-gun delivery, and adenoviruses 
(42). We chose adenoviruses because they are quite easy to use, allow transient transfec­
tion of CAR (coxsackie adenovirus receptor)-positive cells (43), are not integrated into the 
host genome, and can be easily administered locally in vivo, in our case intradermally. 
Usually an unpredictable, certain level of locally induced inflammation follows adenovi­
ral administration and might be considered as a disadvantage. In our experiments, the 
positive effect of trans gene expression was notably higher than the theoretical, negative 
side-effect caused by adenovirus-induced inflammation, as seen by the reduction of bac­
teria demonstrated in Fig.6 and Fig. 7. In our experiments, we used an El and E3 deleted 
adenoviral (Ad5) construct. Literature reveals that administration of lower dosages than 
those we had injected (8.107 and 8.109 plaque-forming units (pfu) rather than 1010 pfus 
as used in our case) are sufficient to generate an immune reaction by recruiting T-and B­
cells, as well as macrophages at day 3 post-transfection, being scored as mild to moderate 
(44). Possibly, the described recruitment of immune-competent cells by an adenovirus is 
not of disadvantage, but actually beneficial in terms of clearance of topical bacteria as in 
our case. Using the LBP-producing virus in wild type mice, reduced the bacterial numbers 
by 44-fold and in knockouts by 4.9-fold, where LBP was restored by the virus. 
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Conclusion 
In a standardized rodent, partial thickness burn wound model we demonstrated that en­
hancing LBP expression at the site of LPS-challenge represented by living, multiresistant 
Pseudomonas aeruginosa, led to decreased bacterial colony growth, both in wild type and 
LBP knockout mice. Based on these observations we conclude that LBP plays an impor­
tant role in innate immune responses against Gram-negative bacterial infection, and that 
stimulation of LBP expression can have a protective effect against wound infection. In 
our hands, adenoviral gene therapy-driven production of LBP in a partial thickness burn 
wound model was feasible. Further investigations are needed to understand the complex 
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Alterations in intradermal gene expression profiles 
by lipopolysaccharide binding protein ( LBP) 






Objective Lipopolysaccharide binding protein (LBP) is important in fighting Gram-negative bacte­rial infection. In previous experiments, topical Pseudomonas aeruginosa colonies were found to be reduced upon overexpression of LBP in a partial thickness bum model in small rodents. The current objective was to investigate intradermal and systemic im­munological alterations in response to bum infliction in the presence or absence of LBP, using an LBP-knockout (LBPko) mouse colony compared to their wild-type (wt) controls. 
Materials Methods Three age/weight matched female C57BL/6 and 3 LBP-knockout mice sustained a 25% total body surface partial thickness bum. Six hours later the bum skin-RNA was extracted and subjected to gene expression profiling. The experiment was repeated including six animals in either group with their skin harvested 24 hours post bum and analyzed for IL-10, TNFa, GR0-1 and IL-6, using real time RT-PCR. Furthermore, differential leukocyte analysis of peripheral blood obtained from each animal was performed. 
Results Gene chip analysis revealed profound changes in intradermal gene expression patterns of one chemokine and several inflammatory cytokines in LBPko versus wild-type animals at 6 hours following bum. The highest expression level was found for the CXC-chemokine growth-related oncogene 1 (GR0-1), with a more than 52-fold up-regulation in knock­outs compared to controls. Total white blood cells, neutrophils and lymphocytes were increased in LBP-knockouts at 24 hours after the bum, when compared to an uninjured state. In contrast, only the numbers of peripheral monocytes in wild-types were signifi­cantly increased at 24 hours. 
Conclusion With regard to intradermal gene expression, LBP-knockout and wild-type mice demon­strated pronounced differences when subjected to a standardized, partial thickness bum wound. The GR0-1 gene revealed a more than 52-times higher expression level in knock­outs compared to control. Profound differences between the animal groups were also noted at 24 hours after the injury in both peripheral leukocyte composition and quantita­tive numbers. LBPko mice reacted with neutrocytosis, lymphocytosis and increased total white blood cells, whereas wild types showed monocytosis at 24 hours after trauma. From this it can be concluded that knocking out LBP has an effect on the rodent's immune system, both locally and systemically when challenged by a bum. Whether LBP itself or possible compensatory mechanisms are responsible for the altered immunity encoun­tered, needs further investigation. 
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I ntroduction 
Burn wounds still represent a challenge for the treating physician, since infected burn 
wounds remain a source of high morbidity and mortality (1). In the US, the lethality aris­
ing from burns in males is roughly 4% whereas in females it is 5.5% (2). In 2010, 450,000 
medical treatments resulting from burns led to 45,000 hospitalizations and on average 
5,000 extensive surgical reconstructions and interventions (3). Because the skin as a de­
fensive barrier is damaged as a result of scald injury, the body needs to respond to invad­
ing bacteria by activating the innate immune system (4, 5). Consequently, inflammatory 
reactions lead to cellular activation and migration. Effector cells such as leukocytes are 
attracted towards the site of injury and contribute to the outcome of the initiated im­
mune response. Among infections, Gram-negative bacteria are challenging to eradicate 
(6, 7), since they favor wound fluids and moist dressings, conditions commonly found in 
burn care treatment. 'Biofilms' are formed, which surround the bacteria with a sticking, 
mechanically protective protein barrier. Despite all efforts and modern methods of treat­
ment, the death toll emerging from Gram-negative sepsis remains high. 
Previously, we have reported on lipopolysaccharide-binding protein (LBP) being produced 
in partial thickness burn wounds of rodents (8). Lipopolysaccharide binding protein, a 
58-60.5 kD acute-phase protein (9), binds with high affinity and specificity to the lipid A 
portion of bacterial lipopolysaccharide (LPS), a major component of the outer membrane 
of Gram-negative bacteria (10). LBP is capable of inducing the production of inflamma­
tory cytokines, recruiting immunocompetent cells, containing invading organisms, and 
clearing noxious substances from wounds. Our group has demonstrated extrahepatic, 
cutaneous IBP-production, while formerly it was solely thought to be produced in the 
liver (11). LBP is thought to play an important role in Gram-negative immune responses. 
Wound healing is an interactive, dynamic process orchestrated by soluble mediators, ex­
tracellular matrix components, as well as resident cells such as fibroblasts, keratinocytes, 
endothelial cells, nerve cells, and infiltrating leukocytes. It is now well accepted that 
chemokines, low molecular weight, secreted proteins, contribute to regulating leukocyte 
influx, and orchestrate the body's response to an immunogenic challenge involving leu­
kocyte trafficking and migration (12-14). 
Using a standardized, infected partial thickness burn model in small rodents, we previ­
ously have conducted experiments aimed at deciphering the role of LBP in topical Gram­
negative bacterial clearance. Since the effects of LBP-LPS interaction under the conditions 




Chapter 3 interested in the intradermal and systemic immunological processes triggered by the absence or presence of LBP. For this, we first performed intradermal gene chip analysis of partially burned skin 6 hours after bum infliction, possibly revealing differences in gene expression levels in LBP-lmockout mice compared to wild-types without infection. In ad­dition, intradermal mRNA levels of pro- and anti-inflammatory cytokines were analyzed at 24 hours after the bum. Finally, we investigated possible differences in peripheral leukocyte subset cell counts in both animal groups in an uninjured state and at 24 hours post-bum. 
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Methods LBPko mouse strain 
LBP knockout mice were received from Douglas Golenbock (Boston University School of 
Medicine} (15). These animals had been backcrossed at least 12 times into the background 
C57BL/6 strain prior to use. All experiments were performed in accordance with the regu­
lations of the National Institute of Health guidelines for the use of laboratory animals, 
and approval was obtained from the University of Michigan Animal Care and Use Com­
mittee. All mice were kept in specific pathogen-free environment under a 12-hour light 
cycle, fed with rodent chow and water ad libidum in micro-isolator containments. For all 
our experiments, we used female 12-14 weeks old, age/weight-matched IBP-knockout 
and wild-type mice. C57BL/6 wild-type animals were purchased from Harlan (Harlan, In­
dianapolis, IN} and allowed at least 5 days for acclimatization prior to use in experiments. 
Mouse burn model and animal groups Animals for gene chip analysis 
Three female C57BL/6 wt mice and 3 age/weight-matched female LBPko mice were 
clipped at their dorsum under general anesthesia (using Ketaset® (Ketamine Hd, 100mg/ 
ml, Fort Dodge, Fort Dodge, IO} and AnaSed® (Xylazine 20mg/ml, Lloyd Laboratories, 
Shenandoah, IO}} applied by intraperitoneal (ip} injection. The animals were then depil­
ated with a depilatory lotion (Nair®,  Carter Products, New York, NY} and placed in a 
mold exposing 25% of their dorsum in a hot water bath (60° Celsius for 10s} by partial 
submersion, creating a partial thickness bum wound, type IIB. The wound size was deter­
mined and calculated following the Meeh formula (16}. Immediately postbum, the skin 
was dried and animals resuscitated with ip saline. Six hours after bum, the animals were 
euthanized by an overdose of ip Pentobarbital (Pentobarbital Sodium SOmg/ml, Abbott 
Laboratories, North Chicago, IL} and the skin harvested under sterile conditions to be 
subjected to intradermal gene expression analysis. Animals for real time RT-PCR analysis at 24 hours postbum 
Six female C57BL/6 mice (Harlan} and six matched in-house bred female LBPko mice were 
treated according to the bum model described above. Following the bum, weight-con­
trolled Buprenorphine (Buprenex®, Buprenorphine Hd, Reckitt & Colman, Richmond, VA} 
was injected subcutaneously well away from the bum site every 6-8 hours. Twenty-four 
hours later, the animals were sacrificed by an overdose of ip Pentobarbital (Pentobarbital 
Sodium SOmg/ml, Abbott Laboratories, North Chicago, IL} . At the time of sacrifice, skin 
samples were harvested under sterile conditions for real time reverse-transcription poly­




Chapter 3 caval vein. A small portion of the whole blood of each animal was mixed with EDTA for use in the Hemavet® (Drew Scientific Inc., Dallas, TX) hematology analyzing system. The remaining volume of the drawn blood was centrifuged at 5,000 g for 5 minutes at 4° Cel­sius, to separate cells from supernatant, the serum was then snap frozen in -80° Celsius for later analysis. 
Tissue samples for gene expression Mouse skin of the partial thickness bum to be subjected to either gene chip analysis or RT-PCR analysis was harvested including the underlying Panniculus carnosus and care was taken not to harvest any muscle tissue. Immediately after weighing, the tissue was snap frozen in liquid nitrogen and stored at -80° Celsius until extraction of RNA. 
RNA extraction, purification and preparation for Affimetrix® 
gene chip analysis RNA isolation All tissue samples were homogenized without being thawed in the presence of TRizol® reagent (Life Technologies Inc., Gaithersburg, MD) and total cellular RNA was purified according to the manufacturer's guidelines (Affimetrix®,  Santa Clara, CA). Thereafter, RNA samples for gene chip analysis were further purified using acid phenol extraction, followed by the protocol for RNeasy® preparation of spin columns (Qiagen, Valencia, Ca). The quality of the extracted RNA was assessed performing a 1 % ethidium-bromide agarose gel electrophoresis to determine intact 18S and 28S bands, and confirmed intact RNA in all samples. 
cRNA Synthesis, Gene Array analysis, 
Gene expression profiling and Statistics For the purpose of this study, gene array analysis was performed in collaboration with the University of Michigan NIDDK Biotechnology Center (supported by NIH grant DK58771). Skin samples were taken at the site of bum, and gene expression levels analyzed in rela­tion to the gene expression of uninjured lung tissue according to the protocols of the NIDDK core facility and then compared to the other group. The preparation of cRNA, as well as hybridization, scanning and finally image analysis followed the manufacturer's protocols and previous publications (17, 18). The arrays were scanned using the GeneAr­ray scanner {Affyrnetrix®). Image analysis was performed with GeneChip software (Af­fyrnetrix®). 
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In short, commercially available high-density oligonucleotide microarrays (version MG_ 
U74Av2 Affymetrix chip, Affymetrix®, Santa Clara, CA) were used, capable of analyzing 
36,000 genes and expressed sequence tags (ESTs) at once. The protocol was set up by 
the University of Michigan Computational Medicine and Bioinformatics, as well as the 
Department of Pathology. There were 20 pairs of features (probe-pairs) on the chip for 
each transcript (probe-set), 20 of which were designed to be complementary to a specific 
sequence (perfect match, PM), another 20 were identical except for an altered central 
base (mismatch, MM). The mismatch probes were subtracted from the perfect match 
values and averaged the middle 50% of the differences as the expression measure for 
that probe. A quantile normalization procedure was used to adjust for differences in the 
probe intensity distribution across different chips. A monotone linear spline to each chip 
was applied that mapped quantiles 0.01 up to 0.99 (in increments of 0.01) exactly to the 
corresponding quantiles of the standard. Then, the transform log[lO0 + max(X + 100;0)) 
was applied to the data from each chip (19). The average intensity for each probe-set was 
computed as the mean of the PM-MM differences, after trimming away the 25% highest 
and lowest differences. For comparison of 2 chips, a two-sided Wilcoxon signed rank test 
was applied to the PM-MM difference after normalization for statistical analysis. 
GR0-1 / KC /  CXCl1 primer-design 
According to the results of the gene chip analysis, the LocusLink and Uni Gene databanks 
(LocusLink No.14825, UniGene No.21013) were used to confirm and identify the gene lo­
cus of interest, which has shown the highest gene expression in the gene chip analysis 
described above. The nucleotide messenger RNA sequence (NCBI nucleotide database: 
NM_008176, Mus Musculus chemokine (C-X-C motif) ligand 1 mRNA (CXCLl ,  also known 
as: growth-related oncogene-1 (GRO-1), also known as: Keratinocyte-derived cytokine 
(KC)),) consisted of 884 base pairs out of which PCR primers were designed for use in real 
time RT-PCR. Forward (5' sequence: CAA TGA GCT GCG CTG TCA GTG, sense) primer and 
reverse (3' sequence: AAG CCT CGC GAC CAT TCf TGA, antisense) primer resulted in a 
139 base pair PCR product. To confirm successful primer design, we back-sequenced the 
resulting PCR product (at University of Michigan, Biomedical Research Core Facility, DNA 
Sequencing Core) and found a 97% consistency with our original design. 
SmartCycler® real time RT-PCR 
Cytokine mRNA levels were analyzed in 6 animals of  each group 24 hrs postbum to com­
pare LBPko versus C57BL/6 wt mice to be subjected to RT-PCR. Total RNA was isolated 
with the TRizol reagent per manufacturer's instructions (Invitrogen, Carlsbad, CA}. Re­





kit (Applied Biosystems, Foster City, CA). Real-time PCR was carried out using the IQ SYBR 
Green Superrnix and the SmartCycler® (Cepheid, Sunnyvale, CA). The GROl /KC/CXCLl , 
TNFa, IL-10 and IL-6 real-time PCR included a denaturation step for 120 sec at 95°C and 
3 temperature-cycles repeated 45 times (94.0°C for 15s, 64.0°C for 15s, 72.0°C for 40s) 
followed by a melting curve from 60.0°C to 95.0°C at o.2°c/second for each sample. The 
comparative threshold cycle (Ct) was used to determine the relative amount of RNA tran­
script between experimental samples (20). PCR products were also examined using a 1 % 
agarose ethidium-bromide gel to confirm the correct size of the PCR product for each 
primer set. Our target gene threshold cycle (Ct) was compared to a housekeeping gene 
of the same sample (glyceraldehyde-3-phosphate dehydrogenase, GAPDH), results are re­
ported as ratios of target gene Ct / GAPDH Ct (20). 
Hemavet blood analysis 
Neutrophils are attracted by chemokines such as GRO-1. In order to assess peripheral 
neutrophil numbers in the blood stream, we analyzed total white blood cell counts, as 
well as neutrophils, monocytes and lymphocyte counts in mouse whole blood at sacrifice. 
To be able to compare the animal ' s  state between uninjured and post-burn, we made a 
baseline evaluation of peripheral blood leukocytes by subjecting 6 unharmed female LB­
Pko and 6 corresponding wild-type mice to whole blood analysis. EDTA anti-coagulated 
blood samples were used to obtain a complete blood count with a Hemavet® (Drew 
Scientific Inc., Dallas, TX) hematology analyzing system. Samples were counted within 
five minutes after the blood was drawn. 
Statistics 
Analysis was performed using Statview® software (SAS Institute, Cary, NC). 
Unless indicated otherwise, data are expressed as the mean ± SE and were compared 
using a two-tailed Student's t test. Statistical significance was assigned at p-values 
< 0.05. 
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Results 
Gene chip data Table 1 shows the outcome of the gene-chip analysis of pooled intradermal RNA of 3 ani­
mals per group harvested from LBPko mice and from C57BL/6 wt having sustained a stan­
dardized partial thickness burn. Affimetrix® gene chip analysis showed 12,500 genes 
out of 36,000 analyzed to be altered and that 1,802 had a more than 2-fold difference 
(increase or decrease) at 6 hours after burn. Out of these, we demonstrate 49 genes 
related to inflammation. 
In the knockout animal group analyzed at 6 hours postburn, the CXC-chemokine GRO-1 
(also known as 'KC', 'MIP2' and 'CXCLl ', the mouse analogue of human interleukin- 8 
(IL-8)) showed an up-regulation of over 52-fold. The differential expression of this gene 
between the LBPko mice and their wild type controls was found to be highest of all. 
With regard to inflammatory cytokines, IL-6 was up-regulated 7-fold in LBPko animal 
skin versus wild-types. IL-la  and IL-10 did not show significance in gene expression be­
tween knockouts and wt mice. A family member of tumor necrosis factor alpha (TNFa), 
TNFa-'protein-2', was found to be down-regulated 2-fold, as were several members of the 
tumor necrosis factor receptor super-families. The skin antimicrobial peptide defensin 
B-2 was down-regulated 3-fold in LBPko mice, as was one receptor involved in binding 
of GRO-1, the CXC-chemokine receptor-2 (CXCR-2). Interleukin-lB  was found to be 3-fold 
down-regulated. Several genes encoding for the heat-shock protein 70 family were found 
to be markedly up-regulated (Table 1 ). 
Quantitative gene expression at 24h after burn 
mRNA expression levels of TNFa, GRO-1, IL-10 and IL-6 of skin samples harvested 24 hours 
after burn infliction were analyzed by real time RT-PCR in both animal groups (Figure 1). 
At this later time point after burn infliction, GRO-1 gene expression levels were found 
to be higher in wild-type mouse skin than in knockouts. The other cytokines studied 
showed no differences in their expression when comparing knockouts and wild-types at 
24 hours post-bum. 
Blood counts 
The analysis of total white blood cells (WBC) of uninjured female IBP-knockout animals 





Table 1:  
Affimetrix® gene chip analysis of skins 6 hours after partial thiclmess burn in control and LBP-lmockout 
mice. 
Pooled, extracted skin mRNA was analyzed as described in Material and Methods. The table shows an 
excerpt of results (49 out of 12,500 regulated genes) of double-sided ('FC either way') Wilcoxon signed 
rank test, expressing up- or down-regulation of genes, comparing LBPko with C57BL/6 wt animals. 
Left column (from top to bottom): genes up-regulated in LBPko mice are expressed in bold; down-regulat­
ed genes are underlined bold and italic; unchanged genes are italic. 
Examples of unchanged gene expression of pro- and anti-inflammatory cytokines are expressed at the 
bottom of this table for completion. 
Genes coding for 
Unigene locus FC either way 
GROl oncogene 52.9 
heat shock 70 kDa protein 4 8.4 
heat shock protein, 110 kDa 8.0 
interleukin 6 7.0 
heat shock protein, 70 kDa 4 3.9 
tumor necrosis factor receptor superfamily. member 11 b (osteoprotegerin) 3.7 
heat shock protein, 70 kDa 3 3.5 
cytokine inducible SH2-containing protein 3, SOCS 3.2 
heat shock protein, 70 kDa 1 3.0 
programmed cell death 8 (apoptosis inducing factor) 3.0 
coxsackievirus and adenovirus receptor 2.9 
interleukin 11 receptor, alpha chain 1 2.9 
chemokine (C-C) receptor 2 2.7 
interleukin 1 receptor, type I 2.6 
tumor necrosis factor receptor superfamily. member la 2.5 
interleukin 10 receptor, beta 2.5 
heat shock 70kD protein 5 (glucose-regulated protein, 78kD) 2.5 
tumor necrosis factor receptor superfamily. member 19 2 .5 
heat shock protein, 110 kDa 2.3 
heat shock protein, 86 kDa 1 2.3 
heat shock 10 kDa protein 1 (chaperonin 10) 2.2 
LPS-induced TNF-alpha factor 2.2 
chemokine (C-X-C) receptor 4 2.1 
tumor necrosis factor, alpha-induced protein 2 2.1 interleukin 1 receptor antagonist 2.1 interleukin 1 receptor. m,e n 2.1 heat shock protein. 25 kDa 2.2 interleukin 6 receptor. alpha 2 .2 tumor necrosis factor receptor superfamily, member 18 2.2 interleukin 3 2.4 
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heat shock protein 30 kDa 
fibroblast growth factor binding protein 1 
heat shock protein. 84 kDa 1 
chemokine {C-Cl receJJtor 1.-like 1 
interleukin 12 receptor. beta 2 
tumor necrosis factor receptor supeifamily. member 1 7  
tumor necrosis factor Oigandl supeifamily member 1 o 
tumor necrosis factor Qigandl supeifamily, member 1 1  
interleukin 3 receptor. alpha chain 
defensin beta 2 
chemokine {C-X-CJ receptor 2 
interleukin 1 beta 
CD4 antigen 
chemokine {C motiO XC receptor 1 interleukin 1 alpha interleukin 10 interleukin 12a interleukin 12b 2.4 2.5 2.7 2.7 2.8 2 .9 3.0 3.0 3.0 3.1 3.4 3.9 4.1 4.3 1.0 1.0 1 .0 1 .0 
When analyzed at 24 hrs following burn and compared to the 'baseline reading' (i.e., at 
an uninjured state) (Figure 3), the data indicated an almost two-fold increase (p <0.002) 
of total WBCs in knockout animals compared to their baseline levels. There was a signifi­
cantly greater nwnber of neutrophils (p <0.02) and lymphocytes (p <0.05) present in the 
blood of the knockout animals at this time point. Figure 4 demonstrates the data of peripheral leukocytes in the wild-type animals at 24 
hours post-bum compared to an uninjured state / baseline reading. While total white 
blood cell counts, as well as neutrophil and lymphocyte counts remained unchanged, 
monocytes showed a significant increase compared to uninjured conditions (p <0.04). 47 II 
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Figure 1: 24 hrs postbum comparison of intradermal gene expression levels of different cyto-/chemo­
kines in LBPko versus wild type mice. 
Skins were harvested 24h after burn infliction, and mRNA levels in these samples were related to GAPDH 
expression by real time RT-PCR. TNFa, GR0-1 and the interleukins IL-10 and IL-6 showed no significant 
difference between LBP ko and wt (C57) controls (bars represent 6 animals/group, + /- 1 SE). 
8 4 
WBC neutrophils lymphocytes monocytes 
Figure 2: Results of total white blood cell and differential leukocyte number analysis of uninjured LBP 
knockout animals versus uninjured wild types. 
Prior to wound infliction, the total WBC count and subset distribution of neutrophils, lymphocytes and 
rnonocytes were determined, comparing LBPko versus wt C57BL/6 controls (C57) in an uninjured state. 
No significance was found (each bar represent 6 animals, + /- 1 SD). 
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Figure 3: White blood cell and leukocyte subset counts at 24h after burn infliction in LBPko mice. 
Comparison of white blood cell (WBC) and leukocyte subset counts between LBPko animals at uninjured 
state (baseline) and at 24 hours following burn. WBC almost doubled (p<0.002), the number of neutro­
phils (p<0.02) and lymphocytes (p<0.05) were significantly increased. Asterisk sign indicates signifi­
cance (n=6 animals per group, +/- 1 SD). 
WBC neutrophils lymphocytes monocytes 
Figure 4: White blood cell and leukocyte subset counts at 24h after burn infliction in C57bl/6 wild 
type mice. 
Comparison of total white blood count and leukocyte subsets of wild-type animals at baseline (C57 base­
line, i.e., uninjured) and of mice 24 hours following partial thickness burn (24 hrs). Monocyte numbers 






Our research is aimed at investigating the effects of LBP in deep partial thickness burns 
using an LBP-knockout mouse colony compared to corresponding wild types. We there­
fore subjected LBP-knockout and wt mice to burn trauma followed by Affimetrix® gene­
chip analysis 6 hours post-burn in order to investigate possible changes in intradermal 
gene expression patterns. The highest level of gene expression was found for the CXC­
chemokine GRO-1, with a more than 52-fold up-regulation in knockouts compared to 
controls. Out of the 36,000 genes analyzed, we found 12,500 to be altered with 1,802 
of which showing a 2-fold difference, and 49 linked to inflammation. Quantitative RT­
PCR data of pro- and anti-inflammatory cytokines generated at 24 hours after the burn 
revealed no difference between the two groups, whereas the GRO-1 gene expression level 
was higher in wt mice at this later point in time. When we compared total leukocyte and 
differential white blood cell counts of mice at an uninjured state, no differences were 
found between both groups. However, peripheral leukocytes almost doubled 24 hours 
following burn in knockouts, when compared to the uninjured state, with neutrophils 
and lymphocytes increased. In contrast, wild type animals reacted with monocytosis 24 
hours after the burn and showed no alteration in the total number of leukocytes. 
Gene-chip analysis using hybridization arrays has advantages and disadvantages. Some 
regard this technology as expensive 'non-hypothesis-driven' (21, 22), others as a very 
useful tool of functional genomics (23, 24). We deliberately chose to analyze at 6 hours 
post-trauma since Endlich and co-workers (25) described this particular time-point ap­
propriate with special regard to inflammatory cytokines. The analysis of 36,000 genes 
of our experiment resulted in only 1,802 (5%) showing an at least two fold difference 
in expression level, when compared to the other animal group, out of which we associ­
ated 49 with inflammation. We expected inflammatory cytokines to be most likely af­
fected, since the trigger for possibly altered gene-expression profiles in both groups, was 
thermal injury. By means of a gene chip analysis we aimed at shedding more light onto 
possible differences in genetic expression profiles of organisms able or unable to pro­
duce LBP, after having sustained a partial thickness burn of considerable size. GRO-1, 
a murine CXC chemokine analogue of human IL-8, was by far the most extensively up­
regulated gene in partial thickness burn wounds of LBP-knockout mice. Interestingly, one 
of the GRO-1 binding receptors, CXCR-2, which plays a role in cutaneous wound healing 
(26), was 2-fold down-regulated in knockout mice. In order to quantify the data gained 
by the gene-chip, we conducted quantitative RT-PCR on inflammatory cytokines at 24 
hours post-burn. Cytokines analyzed and known to play a role in cutaneous inflamma­
tion (27) were TNFa, IL-10 and IL-6 as well as GRO-1, with IL-6 also being altered as seen 
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in our Affimetrix® data. At this later point of time, the differences were not found to be 
significant as opposed to the 6 hour time-point. 
ehemokines such as the oce-chemokine GRO-1 found in our experimental model, are 
produced by leukocytes and tissue cells either constitutively or after stimulation (28) 
and are responsible for leukocyte chemoattraction (29). Due to overlapping function and 
only relative specificity of receptor affinity, a complex picture of oceRs (receptors) bind­
ing oceLs (ligands) in vivo prevails, making multiple options of neutrophil recruitment 
possible (30-33). According to Dunkan and coworkers, ace chemokines IL-8 and GRO­
contribute to inflammatory reactions and suppress PMN apoptosis (34). By blocking the 
ace receptor, neutrophil recruitment can be inhibited as also described by Dunican (35). 
When related to our data, we have found evidence that in LBP-lmockout mice the GRO-
1-receptor OCCR2 was down regulated in contrast to the up regulated GRO-1, which adds 
to Dunican , s discussion about relative specificity of receptor affinity. In a wide variety 
of cells the production of IL-8 or GRO can be induced by inflammatory cytokines at the 
transcriptional level (36, 37), therefore there is clear evidence that these chemokines are 
linked to inflammation and orchestrate leukocyte responses. As both, GRO-1 and the 
binding receptor oceR2 were altered in LBP-lmockout mice used in our model, we contin­
ued to investigate on neutrophils. 
At first, we looked at neutrophil concentration in whole blood at an uninjured state, and 
compared the findings to 24 hours after partial thiclmess burn in both animal groups. 
It is well lmown that tissue injury results in an acute inflammatory reaction, mediated 
by cytokines and chemokines. Neutrophils, as key mediators of inflammation, usually 
constitute nearly 50% of all cells at a wound site, and appear at day 1 after tissue injury 
(38). In our experiment, we found no significant difference in the total number of leuko­
cytes and specifically neutrophils, in either mouse group at an uninjured state. 1\ven­
ty-four hours after partial thiclmess bum, the picture had changed. Knockout animals 
had almost doubled their numbers of systemically circulating leukocytes compared to 
their uninjured state. Significantly more neutrophils and lymphocytes were found in the 
lmockouts as compared to the baseline reading, whereas wild types responded to burn 
infliction by increased monocytes under the same condition. Neutrophils represent an 
important subset of the leukocyte population, are short-lived, polymorphonuclear cells 
that play a key role in the early stages of the inflammatory response to infection by their 
ability to migrate, phagocytose, produce reactive oxygen species and also kill extracellu­
lar microbial pathogens. They are also key components of cutaneous wound healing (26), 
making them especially interesting for an experimental setting such as our burn wound 
model. During infection however, neutrophils leave the blood under the influence of che­
motactic factors like microbial products (fMLP), certain complement components such as 
e5a, and chemokines such as IL-8, or as in this case, the mouse equivalent GR0-1 .  With 
reference to burn wounds or photo-ageing (39), some investigators found that the clear-51 EJ 
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ance mechanisms of neutrophils by apoptosis are impaired in burned skin, caused by an 
extension of their life, which are due to local elevation of cytokine levels and the hypoxic 
conditions (40-42). In our experimental setting, the infliction of a bum had pronounced 
consequences on peripheral leukocyte and leukocyte subset numbers, and changed intra­
dermal gene expression patterns of mice lacking the ability to produce a protein found 
important in Gram-negative infection. 
Conclusion 
In a standardized partial thickness bum wound model, profound alterations in intra­
dermal gene expression levels were found between LBPko and wild type mice. Intrader­
mally, the neutrophil chemoattractant GR0-1 was found to be the highest induced gene 
in LBPko mice analyzed by a gene-chip, early after bum injury. 24 hours after bum, no 
significant differences in intradermal pro- and anti-inflammatory cytokine gene expres­
sion levels were found between LBPko and wt mice using RT-PCR. When mice lack the 
ability to produce LBP, sustain major bum trauma even without infection, at 24 hours 
post-bum they react with neutrocytosis and lymphocytosis, in contrast to wild type mice 
demonstrating monocytosis. This observation implies that substantially different cellular 
immune strategies prevail in the presence respectively absence of LBP. Whether this neu­
trocytosis is GR0-1 dependent, and whether it leads to enhanced neutrophil migration 
into the affected skin, needs to be established, including the kinetics of the processes 
involved. 
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Previously, a burn wound-infection model was created to investigate innate immunity 
and host defense against Gram-negative infection. Application of this model to lipopoly­
saccharide-binding protein (LBP) deficient mice allowed studying the role of this protein 
in immunological reactions of burn wound infections. The purpose of the current study 
was to investigate topical as well as systemic immunological changes in cellular behavior 
and mRNA expression levels in reaction to the burn, over a period of 96 hours. In addi­
tion, we studied the natural bacterial colonization difference between LBP knockout and 
control mice. 
Methods: 
LBP-knockout mice and corresponding wild type controls were subjected to a deep partial 
thickness burn. At 6, 24, 48 and 96 hours following trauma, intradermal mRNA profiling 
was conducted, focusing on the chemokine GR0-1, as well as pro- and anti-inflammatory 
cytokines. Peripheral blood analysis was performed for total white blood cells and leu­
kocyte subsets. A myeloperoxidase (MPO) assay was conducted to measure neutrophil 
oxidative burst intradermally in both groups. The natural bacterial colonization in either 
mouse colony was studied 6 days following the burn wound after having left the burn 
uncovered for the whole period. 
Results: 
GR0-1, TNFa and IL-10 showed a biphasic expression profile in time, with no difference 
between both groups. In contrast, IL-6 exhibited a monophasic profile, with at the later 
time points significantly lower levels in LBPko mice. At 24 and 96 hours following trau­
ma, knockout animals had significantly more leukocytes in their peripheral blood com­
partment compared to wild types, at 96h this number was 4-times as high. In the MPO 
assay higher readings were obtained in wild-type skin at 24 and 96 hours compared to 
the readings in LBP knockout mice. Without wound coverage, the natural colonization 
process resulted in less bacteria on the skin of knockout mice 6 days after the burn. 
Conclusion: 
With this study, we showed that LBP-deficiency led to profoundly changed peripheral 
leukocyte subset numbers, intradermal GR0-1 and IL-6 mRNA expression levels, and 
neutrophil activation status. Furthermore, knocking out LBP affected the immunological 
response not only to Gram-negative bacteria as previously shown, but also to Gram­
positive, when the burns were subjected to a natural bacterial re-colonialisation over a 
period of 6 days following burn. 
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Introduction 
During the past decades, the focus of interest in bum wound infection has shifted from a 
macroscopic to a microscopic level, from the treatment of bum wound related infections 
to understanding the underlying cellular interactions between the host and the patho­
gen. The view has narrowed to a (sub)cellular, molecular level, resulting from a greater 
understanding of protein-receptor interactions and intracellular pathways necessary to 
adequately respond to infections. 
Bum wound infection determines the clinical outcome of wound healing, the incidence 
of complications, and the overall result (1-5). Interestingly, Gram-positive bacteremia ex­
erts no identifiable effect on the predicted mortality of bum patients, whereas Gram­
negative bacteremia significantly increases the death rate above that predicted on the 
basis of extent of bum and patient age (6). In a recent study, factors found to associate 
with bum mortality included age, total and full thickness bum-surface area, female gen­
der and early mechanical ventilation (7). Interestingly, infection-related death is indepen­
dent of the percentage of total body surface area bum, the percentage of full thickness 
bum and inhalation injury (8). Gram-negative bum wound infections are associated with 
high morbidity and mortality (8-10), with Pseudomonas aeruginosa being the most feared 
bacterium (1 1 ). According to Azzopardi and coworkers (2), these Gram-negative infec­
tions are most challenging due to their ubiquity in the natural environment, their high 
prevalence of multidrug resistance and rapid acquisition of resistance causing high death 
rates. Various authors describe high mortality directly or indirectly resulting from post­
bum infections (6, 8, 1 1 ,  12). 
Lipopolysaccharide-binding protein (LBP) represents a central participant in host im­
mune response to Gram-negative infection. LBP binds to the lipid A portion of bacterial 
lipopolysaccharide (LPS, endotoxin), the principal component of the outer membrane of 
Gram-negative bacteria (13). This protein is produced not only in the liver, but also in var­
ious extrahepatic sites, such as wounds (14). LBP enhances binding of LPS to membrane­
bound CD14 (15), a GPI-anchored protein without transmembrane components. The Toll­
like receptor family transmits the LBP-mediated LPS-CDl 4 signal to intracellular signaling 
pathways leading to gene transcription activity (16-18). Previously, we have demonstrat­
ed an inverse relationship between LBP expression in bums and the number of dermal 
bacterial colonies (19). Next to LBP as an acute phase protein, interleukin production is 
triggered by scald injuries as well (20, 21 ). By investigating selected pro-inflammatory 
cytokines, like interleukine-1 (IL-1), IL-6 and tumor-necrosis factor alpha (TNFa), as well 
as anti-inflammatory cytokines with opposing activity like IL-10, an adequate description 





We had homozygous LBP-knockout (LBPko) mice available allowing to obtain further 
insight into LPS-LBP interaction which initiates the immune response within Gram­
negative infected bum wounds. Earlier, we have shown the importance of LBP using 
these knockout mice in a standardized partial thickness bum model when infected with Pseudomonas aeruginosa. We demonstrated that local administration of an adenovirus 
construct encoding for LBP enhanced immunity at the site of infection. The bum wound 
itself is of utmost importance in this context. At the site of bum, intradermal cytokine 
as well as chemokine gene expression (24) is increased, triggering further inflammatory 
cytokine production and cellular chemo-attraction. Consequently, cells of the immune 
system respond and migrate towards the site of injury (25, 26), participate in a topical 
and subsequently systemic inflammatory reaction, with leukocytes orchestrating the im­
mune response. Previously, in a series of experiments, we found no differences in periph­
eral blood leukocyte numbers between wild type (wt) and LBPko mice at an uninjured 
state. However, after having sustained a partial thickness burn, the picture had changed (chapter 3 of this thesis). At 24 hours following the bum injury, knockout mice had almost 
doubled their peripheral leukocytes and neutrophils, while also lymphocyte numbers 
had increased, whereas wild types mice showed increased monocyte numbers only. As 
another consequence of the bum, LBPko mice reacted to thermal injury with the expres­
sion of the chemokine growth-related oncogene-1 (GR0-1) known to attract neutrophils, 
earlier and to a higher degree than wt mice. 
With the experiments described here, we focused on monitoring pro- and anti-inflam­
matory cytokine mRNA levels using quantitative reverse-transcription polymerase-chain 
reaction (qRT-PCR), at up to 96 hours following partial thickness burn. We hypothesized 
that neutrophils would find their way in response to intradermal GR0-1 expression, dis­
covered in previous experiments to be extensively up regulated at 6h and 24h postburn, 
in both LBPko and wt mice. Therefore, we monitored systemic leukocytes including their 
subsets at up to 96 hours as well as studied neutrophil accumulation intradermally, in 
both wt and LBPko groups. Furthermore, we hypothesized that without inflicting a de­
fined Gram-negative infection, intradermal neutrophil accumulation would be capable of 
influencing the natural course of a bacterial re-colonialisation of our standardized burn 
wound. Therefore we subjected IBP-knockout mice and wild-types to the partial thick­
ness burn, and had their wounds uncovered for 6 days followed by quantitative bacterial 
counts. 
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Materials, Methods 
Animals 
LBP lmockout mice were a gift from Douglas Golenbock (Boston University School of 
Medicine) (27). We had the animals backcrossed at least 12 times into their C57BL/6 back­
ground-strain prior to use. All experiments were performed according to the regulations 
of the National Institute of Health guidelines for the use of laboratory animals and ap­
proval was obtained from the University of Michigan Animal Care and Use Committee. 
Mice were kept in specific pathogen-free environment under a 12-hour light cycle, fed 
with rodent chow and water ad libidum in micro-isolator containments. For all experi­
ments, we used 12-14 weeks old female, weight- and/or age-matched mice. C57BL/6 wt 
animals were purchased from Harlan (Harlan, Indianapolis, IN), allowing at least a 5 day 
period of acclimatization prior to experiments. 
Burn model, without infection 
Twenty-four female wt mice from Harlan (Harlan, Indianapolis, IN) and 24 in-house bred 
female LBPko mice were age/weight-matched. Out of these, 4 random groups of knock­
outs and wild-types were formed. All animals were clipped at their dorsum under general 
anesthesia (Ketaset® (Ketamine HCl, lO0mg/ml, Fort Dodge, Fort Dodge, IO), AnaSed® 
(Xylazine 20mg/ml, Lloyd Laboratories, Shenandoah, IO)) applied intraperitoneally (ip). 
After depilation (Nair®, Carter Products, New York, NY), the animals were placed in a 
mold exposing 25% of their total body surface area at their dorsum in a hot water bath 
by partially submerging (60° Celsius for 10s), creating a deep partial thiclmess bum 
wound. The desired bum wound size was determined by the Meeh formula (28) before 
infliction. Immediately postbum the skin was dried and animals resuscitated with ip 
saline, and buprenorphine (Buprenex®, Reckitt & Colman, Richmond, VA) was injected 
subcutaneously every 6-8 hours for 2 days well away from the bum site. Next, six animals 
of each group (LBPko and wt) were euthanized after 6, 24, 48 and 96 hours by an overdose 
of ip Pentobarbital (Sodium Pentobarbital S0mg/ml, Abbott Laboratories, North Chicago, 
IL) to be subjected to dermal tissue harvest (for RNA extraction for qRT-PCR analysis and 
MPO analysis). Peripheral blood samples were also taken at the 24, 48 and 96 hour time 
point to be analyzed for peripheral leukocytes and leukocyte subsets (Hemavet®). 
Burn model plus natural bacterial colonization 
Another twelve animals, six wt versus 6 LBPko mice, were burned and left with uncov­




course of bacterial re-colonization. Resuscitation and pain management was the same 
as described above. Quantitative bacterial counts were conducted on day 6 postburn. 
Burned skin was harvested under sterile conditions, weighed and homogenized in saline 
on ice. Homogenates were plated in serial dilutions in triplicates (102 , 104, 106) on 5% 
sheep-blood agar plates. The following day, bacterial colonies were counted in a blinded 
fashion and standardized per g/skin, presented as calculated mean of plates ( + /- 1 stan­
dard error, SE), out of triplicates. Bacterial typing was done by morphology. 
Gene expression ana lysis by rea l  time RT-PCR 
All skin samples were homogenized without being thawed in the presence of TRizol re­
agent (Life Technologies Inc., Gaithersburg, MD) and total cellular RNA was extracted 
according to the manufacturer's guidelines. The samples were then subjected to the 
RNeasy® preparation protocol for spin columns (Qiagen, Valencia, CA). Reverse tran­
scription was carried out using the high-capacity cDNA reverse transcription kit (Applied 
Biosystems, Foster City, CA). Real-time PCR was carried out using the IQ SYBR Green Su­
permix and the SmartCycler® (Cepheid, Sunnyvale, CA). 
The GRO-1, TNFa, IL-10 and IL-6 quantitative RT-PCR (SmartCycler®, Cepheid, Sunnyvale, 
CA) included a denaturation step for 120 sec at 95°C and 3 temperature-cycles repeat­
ed 45 times (94.0°C for 15s, 64.0°C for 15s, 72.0°C for 40s) followed by a melting curve 
from 60.0°C to 95.0°C at o.2°c/second for each sample. IL-6 primers were received from 
R + D Systems Inc. (Minneapolis, MN), mouse IL-10 sense primer was: CCAGTTTTACCTG­
GTAGAAGTGATG, IL-10 antisense primer: TGTCTAGG CCTGGAGTCCAGCAGACTC, mouse 
TNF sense primer CTGTAGCCCACGTCGTAGC, and antisense primer TTGAGATCCATGCC­
GTTG. GRO-1 primers were designed as described in chapter 3 of this thesis: forward 
/5' sequence: CAA TGA GCT GCG CTG TCA GTG, sense, reverse / 3' sequence: AAG CCT 
CGC GAC CAT TCT TGA, antisense. PCR products were also examined using a 1 % agarose 
ethidium-bromide gel to confirm the correct size of the PCR product for each primer set. 
Our target gene threshold cycle (Ct) was compared to a housekeeping gene of the same 
sample (glyceraldehyde-3-phosphate dehydrogenase, GAPDH), results are reported as ra­
tios of target gene Ct / GAPDH Ct (29). 
Myeloperoxidase (MPO) assay of ski n  samples 
Neutrophil infiltration and presence in the skin was quantitated by measuring MPO ac­
tivity according to a modification of the Goldblum-protocol (30, 31). Skin samples were 
homogenized for 1 minute on ice in homogenization buffer (HTAB, hexadecyl-trimeth­
ylammonium bromide), 0.SM EDTA, mono- and dibasic potassium phosphate and Hp). 
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Next, the samples were continuously sonicated three times for 10 seconds, 1 ml was 
transferred and spun at 15,000 rpm for 15 min. in 4° C. Assay buffer (containing mono­
and dibasic potassium phosphate, 0.3% Hp2 and ODH (o-dianisidine HCL)) was prepared 
shortly before the assay. An ELISA plate reader was set to read the change in absorbance 
at 465 nm every 1 Os for 90s per well. Next, 20 µl of sample were pipetted into a 96 ELISA 
plate in triplicates per sample, 200 µl assay buffer per well were added and reading was 
started immediately thereafter. MPO units were calculated as the change in absorbance 
over a reading-period of 90 s (delta OD (optical density)) per well and mean of triplicate 
wells per sample were analyzed and calculated. Peroxidase activity was thus determined 
by measuring the rate of conversion of o-dianisidine to its colored product in the pres­
ence of Hp2 • 
Hemavet® b lood a na lysis 
Whole blood of LBPko and C57BL/6 wt controls was analyzed for peripheral white blood 
cell counts, including neutrophils, monocytes and lymphocytes at sacrifice. EDTA anti­
coagulated blood samples were subjected to analysis in Hemavet® Mascot Multispecies 
Hematology System Counter 1500R (CDC Technologies, Inc., Oxford, CT). Samples were 
counted within five minutes after blood was drawn. 
Statistica l analysis 
Statistical analysis was performed using StatView software (SAS Institute, Cary, NC). Data 
shown express mean value ± 1 SEM (standard error), comparison was performed using 





Results In intradermal gene-chip analysis and qRT-PCR done earlier, we found altered gene ex­pression levels of the chemokine GRO-1 as a response to burn trauma in both LBPko and wt mice. Here, intradermal mRNA levels of GRO-1 were obtained at 6, 24, 48 and 96 hours following partial thickness burn infliction (Figure 1 ). Using real time RT-PCR, GRO-1 expression levels were shown to follow a biphasic course, with the highest expression at 24 hours in both animal groups. At 6 hours, LBPko animals had a higher expression (p<0.001) than the wt, whereas at 24 hours wt animals showed higher GRO-1 expression (p< 0.01). No difference was observed at 48 and 96 hours post-trauma. As seen in Figure 
2, the inflammatory cytokine TNFa, as GRO-1, also showed a biphasic pattern, with no significance between the groups. When analyzing the gene-expression levels of the anti­inflammatory cytokine IL-10, the same biphasic expression and kinetics thereof was seen as observed for TNFa and GRO-1 (Figure 3). Also for IL-10, no significance was found when comparing the two groups. As demonstrated in Figure 4, IL-6 did not follow the biphasic patterns of the other inflammatory cytokines, neither in LBPko mice nor in wt controls. IL-6 levels of LBPko mice dropped approximately 10-fold below those of C57BL/6 mice at 48 and 96 hours after burn. Besides cytokine profiles, we also studied leukocyte changes at 24, 48 and 96 hours after the burn. Figure 5 shows the total peripheral white blood cell (WBC) counts of both wt and LBPko mice. At 96 hours following burn, the total number of WBC in the peripheral blood of LBPko animals was significantly, almost 4-times higher than in wild-types. As demonstrated in Figure 6, no difference was found in peripheral neutrophil numbers. Lymphocyte numbers (Figure 7) were found to be higher in LBPko animals at 24 and 96 hours. At 96 hours after burn, there were 4-times as many lymphocytes in knockout mice as there were in wt animals. As for monocytes at the 48-hour time point, LBPko animals had lower numbers, as shown in Figure 8. In order to study neutrophil numbers and/or activation intradermally, we analyzed my­eloperoxidase in skin extracts of both groups (Figure 9). This assay quantitates the oxida­tive burst of neutrophils. At 24 hours post burn, statistically significantly higher MPO readings were detected in the skin of wild type mice, suggesting the presence of more neutrophils or neutrophils with higher oxidative bursts intradermally in this group. When the animal skin was left uncovered and therefore unprotected against contamina­tion, there was less bacterial growth (p=0.03) on the skin of LBPko mice at 6 days post­burn compared to the growth on the skin of wt (Figure 10). The six day period revealed a mixture of Gram-positive bacterial infection namely of Staphylococci and Streptococci. 64 
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Figure 1: Intradermal GR0-1 mRNA expression levels in burned skin of LBPko mice compared to wt 
mice in time after bum trauma 
Animals were burned and GRO-1 mRNA samples of LBPko versus wt mice were taken at several time 
points, and mRNA levels were assessed by real time RT-PCR as described in Materials and Methods. At 
6 and 24 hours after the burn, GRO-1 mRNA expression levels were statistically different. (n=6 animals 
/ group). Asterisks indicate significance between the groups (6 hours p<0.001, 24 hours p<0.01 ,  data 
show +/- lSE). 
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Figure 2: Intradermal TNFa mRNA expression levels in burned skin of LBPko and wt mice at several 
time points up to 96 hours after bum infliction. 
At different time points after inflicting the standardized burn, TNFa mRNA levels were analyzed by real 
time RT-PCR as described in Materials and Methods. At 24 hours postburn, the maximum mRNA expres­
sion is seen in both groups. In time, wt (C57) and LBPko animals show comparable mRNA expression 
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Figure 3: Intradermal IL-10 mRNA expression levels in burned skin of LBPko versus wt in time after 
burn trauma. 
As described in Material and Methods, the IL-10 mRNA levels were assessed by qRT-PCR at different time 
points following standardized burn, comparing knockout and wt mice. The anti-inflammatory cytokine 
IL-10 revealed a peak at 24 hours and showed no difference in expression profiles and kinetics between 
the groups (n=6 animals per data point, +/- 1 SE). 
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Figure 4: Intradermal IL·6 mRNA levels comparing knockout mice with wt in time after burn. 
At different time points after inflicting the standardized burn, IL-6 mRNA levels were assessed by real 
time RT-PCR as described in Materials and Methods. The IL-6 mRNA levels remained higher at 48 and 96 
hours in wt mice following burn compared to their levels in LBPko mice. Asterisks indicate significance 
(p <0.05 at 48 and 96 hours, n=6 animals per data point, + /- 1 SE). 
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Figure 5: Analysis of total white blood cell counts in LBPko versus wt mice in time after burn inflic­
tion. 
At different time points after inflicting the standardized burn, total white blood cell count was per­
formed as described in Materials and Methods. At 24 and 96 hours following the trauma, LBPko animals 
have significantly more leukocytes (WBC) in their peripheral blood than the wt, at 96 hours this numbers 
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Figure 6: Peripheral blood neutrophil counts in LBP-knockout mice versus wt in time after burn inflic­
tion. 
As described in Material and Methods, whole blood neutrophil numbers were assessed at different time 
points after inflicting the standardized burn. The neutrophil numbers (NE) were found to be not signifi­
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Figure 7: Peripheral blood lymphocyte cell counts in LBPko mice versus wt in time after burn inflic­
tion. At different time points after inflicting the standardized bum, whole blood lymphocyte numbers were assessed as described in Materials and Methods. More peripheral lymphocytes (LY) were found in knock­out mice at 24 and 96 hours following bum compared to wt controls. At 96 hours following burn, there were approximately 4-times as many lymphocytes in the blood of knockouts than in blood of controls. Asterisks indicate significance (p<0.05, n=6 animals per data point, +/- 1 SE). 
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Figure 8: Peripheral blood monocyte counts of LBPko versus wt at up to 96 hours after burn. At different time points after inflicting the standardized burn, whole blood monocyte numbers were assessed as described in Materials and Methods. At 48h after bum, there were more monocytes in the blood ofwt mice compared to LBPko. Asterisk sign indicates significance (p<0.05, n=6 animals per data point, + /- 1 SE). 
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Figure 9: Myeloperoxidase assay analysis of skin samples of LBPko mice versus wt subjected to partial 
thickness burns at up to 96 hours after bum. Skin samples of mice were subjected to an MPO assay as described in Materials and Methods. The MPO assay allows for detection of oxidative bursts of neutrophils. At 24 hours, MPO readings were signifi­cantly higher in C57BL/6 wt mice compared to LBPko. Asterisk sign indicates significance (p<0.05, n=6 animals per data point, + /- 1 SE). 
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Figure 10: Comparison of bacterial growth on uncovered skin of I.BP knockout mice versus wt at 6 





Discussion Earlier, we developed a partial thickness burn model in LBP-knockout and wt control mice to study Gram-negative infection. As a result of dermal gene chip analysis and qRT-PCR we had found altered intradermal gene expression profiles of the chemokine GRO-1 at 6 hours and 24 hours post-bum. With the experiments described here, we focused on mon­itoring pro- and anti-inflammatory cytokine mRNA levels up to 96 hours. GRO-1, as well as IL-10 and TNFa showed a biphasic pattern of mRNA expression, whereas IL-6 demon­strated a monophasic pattern. IL-6 revealed an almost 10-fold lower expression in LBPko mice at 48 and 96 hours, whereas TNFa and IL-1 O did not show significant difference be­tween the two groups of mice. GRO-1 is known for neutrophil chemoattraction, therefore systemic leukocyte numbers including their subsets at up to 96 hours were monitored, as well as neutrophil accumulation intradermally at the site of burn in both wild type and LBP knockout mice. 96 hours post burn, LBPko mice had almost doubled their total WBC numbers in peripheral blood, and demonstrated lymphocytosis, whereas knockout mice had less monocytes at 48 hours after burn. For neutrophil detection, an MPO assay was performed on burned mouse skin and showed lower readings in LBPko at 24 hours. Considering the role of chemokines and neutrophils in topical bacterial clearance in our burn model, we were interested in the natural course of bacterial re-colonialisation from surrounding skin. We thus left their burn wounds uncovered for 6 days, followed by quantitative bacterial counts, which showed especially Gram-positives on both wounds and less bacterial numbers on knockout skin. In the current set of experiments, we found biphasic mRNA expression levels of TNF and IL-10, as well as of GRO-1. Not only GRO-1, but also the pro- and anti-inflammatory cytokines studied, demonstrated their maximum mRNA expression levels at 24 hours after the injury. With regard to the inflammatory process of wound repair / regenera­tion, it is accepted that cytokine expression induction occurs in a time dependent man­ner and is subsequently followed by cellular inflammatory reactions (32-34). According to Feezor and co-workers (35), cutaneous gene expression after a second degree burn follows a transient and time-dependent regulation, peaking at 3 and 14 days after the burn. When each cytokine, including GRO-1, was analyzed individually over the period of 96 hours, our results indicated a peak expression at 24 hours post-bum in contrast to Feezor ' s results. IL-6 was the only cytokine showing a difference in expression kinetics between wt and knockouts, being higher expressed at 48 and 96 hours in wt than in LBP­knockout animals. Severe burns per se are thought to act in two inflammatory phases in a time dependent manner and therefore initiate an immune response. The first reaction of the organism is of a systemic inflammatory response syndrome (SIRS), followed by an anti-inflammatory phase (CARS) characterized by a profound immune-deficiency through 
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cellular deprivation (36), which can be seen as a biphasic response (37). The time-course 
of both, especially with regard to our knockout model, is unknown. In our current study 
we have noted a biphasic response in TNFa, IL-10, and GRO-1 at 24 and 96 hours after 
the burn, which fits well with the biphasic, but time wise unpredictable SIRS - CARS 
phenomenon (38). 
When subjecting our burn model to commercially available gene-chip analysis at 6 hours 
post-bum, the chemokine GRO-1 showed a striking intradermal up-regulation in LBPko 
mice compared to wt under the same condition. Since GRO-1 is known to chemoattract 
neutrophils, we were interested in whether this increased GRO-1 expression early in the 
reaction to bum, persisted and was possibly associated with increased accumulation of 
neutrophils at the site of GRO-1 expression, leading to higher numbers of neutrophils 
in the dermis of knockout mice after being burned. Leukocytes follow chemokine mRNA 
expression with a certain delay. We have therefore chosen several different time points 
to study peripheral total white blood cell and leukocyte subset counts. The time-line we 
have chosen is in accordance with Lederer's group (39), who focused on leukocyte gene 
expression profiles in the peripheral blood pool at 2 hours, 1 day, 3 days and 7 days fol­
lowing a scald injury or sham. In their study, the authors concluded that the highest gene 
expression level of mouse leukocytes was seen at 1 day following trauma. 
The chemokine GRO-1 is believed to be the murine analogue of human IL-8 (40, 41) known 
for neutrophil chemoattraction. Neutrophils play a central role in modulating and orches­
trating the immune response triggered by invading pathogens, and were of interest to 
investigate in our model since GRO-1 expression kinetics was strikingly altered due to 
the absence of LBP. An MPO assay makes the detection of neutrophils in tissue possible, 
since it detects the oxidative burst of neutrophils, which can be increased due to more 
neutrophils at site or due to them being more activated. Skin MPO readings of C57BL/6 
were found to be higher at 24 hours post-bum compared to the readings in LBPko, rising 
in parallel with knockouts as time progressed. Since, as indicated before, cellular immune 
reactions seen in leukocyte subsets being attracted to the site of inflammation follows 
gene expression with a delay of one day, we started our MPO analysis at 24 hours follow­
ing burn. It is possible that the time point we have chosen to begin analyzing neutrophils 
intradermally was too late and only reflected the kinetics in wt mice adequately, thus 
possibly giving an incomplete picture. To our knowledge, neutrophil behavior with refer­
ence to host immunity in LBPko mice having sustained burns has not been studied yet. To 
obtain a better picture of this early kinetics, future studies need to focus on neutrophils 
in LBP-knockout mice and their possible intradermal presence at earlier time points post­
bum. 
With regard to the peripheral blood pool of leukocytes, we found that the total number 
of leukocytes was higher in knockouts at 24 hours after bum. At 96 hours, knockouts 





increase found in LBPko mice was attributable mainly to lymphocyte increase, and indi­
cates a profoundly different strategy of post-bum inflammation response. This diverse 
cellular immune reaction between knockouts and wt has potential effects on coping with 
infections like those in our bum wound model. In order to gain more information, we 
stepped from a defined infection protocol, as conducted in our previous experiments, to 
a natural course of bacterial re-colonialisation. Regularly, bum wounds are found to be 
sterile after the injury and become re-colonialized over time from the surrounding skin 
flora. After 6 days we found that the majority of the bacteria encountered in both groups 
were Gram-positive, which corresponds with naturally occurring, surrounding skin flora. 
Unexpectedly, 20.6-fold more Gram-positive bacteria were found on the skin of wild type 
mice. The clearance of Gram-positive bacteria involves the protein lipoteichoic acid (LTA) 
followed by binding to the TLR2 system in contrast of binding to the TLR4 complex, 
which is used by the LBP/LPS complex of Gram-negative bacteria (42, 43), as previously 
shown. One would therefore expect, that Gram-positive bacterial clearance was indepen­
dent of LBP-ablation as seen in LBPko animals, in contrast to the observed 20-fold less 
Gram-positive bacteria. Possibly, 'compensatory' immunological mechanisms leading to 
reduced Gram-positive bacteria in bum wounds of LBPko animals account for this obser­
vation and need further exploration. Within our experiments, we possibly revealed sup­
port for Golenbock · s theory that a mechanism exists that compensates for missing LBP 
(27, 44), which has also been proposed by this very group, who created the LBPko mouse 
model in the first place. 
Conclusion 
LBP-deficiency in knockout mice used in a standardized bum wound model led to pro­
foundly changed peripheral leukocyte and leukocyte subset numbers, as well as IL-6 and 
GRO-lintradermal mRNA levels when compared to wt mice over a time course of 96 
hours. At the bum site, the intradermal accumulation of neutrophils revealed lower read­
ings in LBPko mice, indicating lower numbers or less activated neutrophils in knockout 
animals. Furthermore, we observed less Gram-positive bacteria on the skin of knockout 
mice as a result of natural re-colonialisation. The complex immunological interactions 
of leukocyte subsets and the complexity of spatiotemporal cytokine expression locally 
at the site of the wound, all influencing topical Gram-positive as well as Gram-negative 
bacterial growth, justifies further studies focusing on the compensatory mechanisms 
prevailing in infections in LBPko mice. 
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Chapte r 5 
Antimikrobielle Peptide und Fibrinkleber in 
Verbrennungen 
Ein Gemisch aus einem antimikrobielle Peptid und Fibrinkleber behalt biologische 
Potenz in vitro und gegen multiresistente Pseudomonas aeruginosa Bakterien in Ver­
brennungen der Tiefe Ilb in vivo 
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Hintergrund: Antimikrobielle Peptide sind natiirlich vorkommende kationische Peptidmolekille. Die erste Verteidigungslinie der Verbrennungswunde stellt das angeborene Immunsystem dar, deren Bestandteile diese Peptide sind. Um die topische Anwendbarkeit in infizierten Verbrennungswunden zu vereinfachen wurde die Wirksamkeit in Fibrinkleber in vivo und in vitro getestet. 
Material und Methoden: Nach in vitro Testung erhielten 15 mannliche Sprague-Dawley Ratten eine tief-zweitgradi­ge Verbrennung und wurden mit multiresistenten Pseudomonas aeruginosa infiziert und mit PG-1 (lO0ug/ml, n= S), Fibrinkleber (n= S) oder einem Gemisch aus beiden (n= S) to­pisch behandelt, die Wirkung wurde zuvor durch einen Radial-Diffsusionsassay bestatigt. 24 Stunden spater wurde die verbrannte und infizierte Haut gewonnen und die Bakteri­enanzahl pro Gramm Haut bestimmt. 
Ergebnisse: 
In vitro lieB sich die biologische Aktivitat bestatigen. Die Gruppe aus entweder PG-1 oder Fibrinkleber zeigte in vivo keine signifikanten Unterschiede in der Bakterienanzahl, hin­gegen lieB sich in der Gruppe des Gemisches eine signifikante antibakterielle Wirkung nachweisen (p<0,04 und p<0,01). 
Schlu&folgerugen: Eine Mischung aus dem antimikrobiellen Peptid PG-1 und Fibrinkleber reduziert die Bakterienzahl eines definierten Infektes einer llb-Verbrennung in vivo signifikant im Ver­gleich zu den Kontrollgruppen. 
Schliisselworter: Verbrennung, angeborenes Immunsystem, Infektion, antimikrobielle Peptide, Fibrinkle­ber 
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Abstract: 
Background: 
Antimicrobial peptides are naturally occurring cationic peptide. The first line of defense 
in infected bums is the innate immune system of which antimicrobial peptides are es­
sential parts. To facilitate their topical use in infected partial thiclmess bums, the efficacy 
of a mixture of the antimicrobial peptide PG-1 with fibrin glue in vitro and in vivo was 
tested. 
Methods: 
After in vitro tests, 15 male Sprague-Dawley rats received partial thiclmess bums; fol­
lowing, the wounds were infected with multiresistant Pseudomonas aeruginosa. Animals 
received either the antimicrobial peptide Protegrin-1 (PG-1) (100µ,g/ml, n=5), fibrin glue 
(n = 5) or a mixture of both (n = 5) topically, efficacy was previously proven by radial diffu­
sion assay. After 24 hours, the infected and burned skin was harvested and quantitative 
bacterial counts per Gram skin performed. 
Results: 
The biologic effect of the peptide was confirmed in vitro. The PG-1 group and the fibrin 
glue group did not show significant differences in bacterial numbers, whereas the mix­
ture group showed significant reduction in Pseudomonas in vivo (p<0.04 and p<0.01). 
Conclusion: 
A mixture of an antimicrobial peptide and commercially available fibrin glue is capable 
of significantly reducing bacteria in infected partial thiclmess bums in vivo compared to 
their controls. 
Key words: 





Infizierte Brandwunden stellen eine Quelle hoher Morbiditat und Mortalitat dar. Die feh­
lende Schutzfunktion verbrannter Haut erleichtert eine rasche Infektion aus bakterieller 
Kolonisation. Unbehandelt kann je nach Keimspektrum, Infektdauer und Resistenz des 
betroffenen Organismus, je nach Virulenz, Art und Ausdehnung der Verbrennung ein 
,,systemic inflammatory response syndrome" (SIRS), Multiorganversagen und Sepsis fol­
gen. Aus einem lokalen Wundproblem wird ein den gesamten Organismus bedrohendes 
Krankheitsbild. Ein Fundament der Therapie des Schwerbrandverletzten stellt die lokale 
antibakterielle Therapie dar. Topische Antibiotika sind zwar effektiv, fiihren jedoch unter 
Umstanden zur Resistenzentwicklung und/oder der Allergisierung. 
Eine neue Substanzgruppe, antimikrobielle Peptide (AMPs), sind natiirlich vorkommende 
Peptidmolekille mit sehr breiter Wirkung gegen Gram-positive und Gram-negative Bak­
terien, Viren (mit Lipidhi.illen) und Pilzen. Sie werden als alte evolutionare Waffen (1] 
bezeichnet, die eine ,,Achillesferse" der attackierenden Einzeller angreifen, namlich deren 
Zellmembran, die sich prinzipiell strukturell von der der Mehrzeller unterscheidet. AMPs 
werden bei Tieren, Pflanzen und dem Menschen beschrieben, sind seit ca. 70 Jahren be­
kannt und werden nicht nur in der medizinischen Forschung, sondern auch in der Tabak­
industrie und im Kartoffelanbau zur Ertragssteigerung eingesetzt [2]. 
Verbrennungswunden weisen nicht nur Eintrittspforten fiir Mikroorganismen auf, son­
dern i.iber sie gehen Fli.issigkeit und EiweiEe verloren. Einen kutanen WundabschluB im 
Rahmen der Heilung bewirkt Fibrin und die stufenweise ablaufenden Phasen der Gerin­
nung. Das Rationale des Einsatzes von Fibrinkleber besteht darin, das Einsprossen von 
Immuneffektorzellen und epithelbildenden Zellen zu erleichtern und die fri.ihen Stufen 
der Wundheilung in Gang zu setzen. Allerdings bietet natives Fibrin ein Nahrmedium fiir 
Bakterienwachstum, dem es entgegenzuwirken gilt. Die naheliegende Idee, Antibiotika 
zum Fibrinkleber zu mischen und dadurch einerseits die Angriffsflache des Kleber-Anti­
biotikagemisches zu vergroBern sowie die Kontaktdauer zu verlangern und andererseits 
die unerwi.inschten Nebenwirkungen zu reduzieren um gleichzeitig lokale antimikro­
bielle Effekte zu erzielen, wurde bereits unter verschiedenen Gesichtspunkten mehrerer 
Forschergruppen untersucht und publiziert [3-5]. Im aktuellen innovativen Ansatz wird 
Fibrinkleber als Vektor zur Applikation der AMPs eingesetzt. Daten zu diesem Vorhaben 
liegen derzeit noch nicht vor, technische Details sind noch nicht etabliert. 
Ziel der vorliegenden Studie war daher die Frage, ob antimikrobielle Peptide gemischt 
mit Fibrinkleber potente Effektoren der Bakterienhemmung in infizierten Brandwunden 
sein konnen. 
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Material und Methoden: 
In vitro Experimente : 
Protegrin-1: 
Das unsererseits verwendete antimikrobielle Peptid Protegrin-1 (PG-1), urspriinglich aus 
Schweineneutrophilen isoliert, wurde entsprechend der publizierten Strukturformel [6] (Abbildung 1) aus 18 Aminosauren und 2 Disulfidbriicken kommerziell in Auftrag gege­
ben und hergestellt (BioSynthesis, Lewisville TX, USA). Das gelieferte lyophilisierte Peptid 
wurde entsprechend den Vorgaben des Herstellers gelost und dadurch in die biologisch 
aktive Form transferiert, die Effektivitat des Proteins wurde durch Radial-Diffusions-As­
says getestet [7] .  
Radial-Diffusions-Assay: 
Mittels eines Rqdial Diffusion Assay (bakterieller Wachstumshemmtest gegen antibakte­
riell wirksame Substanzen) wurde die in vitro-Aktivitat des neuen Gemisches aus Prote­
grin-1 und dem Gewebekleber iiberpriift. Zusammengefasst bestand die erste der zwei 
Schichten aus 1 %-Agarose (Sigma Chemical, St. Louis, MO USA) und 0,03% Trypticase Soy 
Broth mit lOmM Natriumphosphat und lOOmM Nad bei einem pH von 7,4. Die nach­
folgende Abdeckschicht be stand aus 6%igem Tryticase Soy Broth und 1 %iger Agarose 
in phosphatgepuffertem Kochsalz. Als Kontrollorganismus wurde hier E.coli (eingestellt 
auf 200µ1 mit 4xl 07 Bakterien) mit 10ml des ersten Mediums gemischt und in 10cm Pe­
trischalen ausgegossen. Nach dem Erstarren wurden 3mm-Locher in das Zentrum des 
Agars gestanzt und mit 30µ1 der jeweiligen Testsubstanzen gefilllt (Tabelle 1) .  Das Sealer 
Protein, der Fibrinolyse-Inhibitor, Thrombin und Calziumchlorid wurden entsprechend 
den Vorgaben des Erzeugers (Baxter Healthcare, Glendale, CA USA) gemischt und kurz­
fristig bei 37°C gehalten, bis die Komponenten verwendet wurden. Gentamyzin mit ei­
ner Konzentration von 3, 16 µg/ml wurde als Positiv-Kontrolle desselben Volumens im 
zentralen Stanzloch appliziert. Nachfolgend wurden alle Platten denselben Bedingungen 
PG-1 RGGR L C Y C RRRF C V C V GR* 
PG-2 RGGR L C  Y C RRRF C I C  V --* 
PG-3 RGGG L C Y C RRRF C V C V GR* 
PG-4 RGGR L C  Y C RGWJ: C F C  V GR* 
PG-5 RGGR L C Y C RPRF C V C V GR* 
Protegrin-1 
Abbildung 1 .  Primare und Sekundare Struktur van Protegrin-1 




Konzentration Kleberprotein Thrombin PG-1, Volumen 
(Mischung von Kleberprotein + Losung Losung 100 µg/ml pro Well 
Fibrinogen / PGl) ( + Aprotinin) (+ Cad2) 
1:1 7,5 µl 7,5 µl 15 µl 30 µl 
1:2 5 µl 5 µl 20 µl 30 µl 
2:1 10 µl 10  µl 10 µ1 30 µl Tabelle 1. Aufbau der in vitro-Studie: Konzentrationen und Verhfiltnisse von PG-1 und dem Fibrinkleberge­
misch mit seinen Komponenten Abbildung 2. Radial Diffusion Assay (Durchlichtbetrachtung): Hemmung von Bakterienwachstum durch 
PG-1 (.,PG" und .,P"), Fibrinkleber (.,FIB" und .,F") und verschiedenen Mischungsverhfiltnissen (F:P) der 
beiden Komponenten. Zentral die Positiv-Kontrolle durch Gentamyzin ausgesetzt und bei 37°C fiir 3 Stunden inkubiert, danach folgte das Abdecken durch den zweiten, nahrstoffreichen Agar {10ml) als overlay. Nach 18 Stunden Inkubation in einem Brutschrank bei 37°C, wurden die Platten analysiert. Die klaren Zonen um die Stanzlocher lassen auf gehemmtes Bakterienwachstum schlieBen (positives Ergebnis}, wohingegen der restliche Agar triib, da mit Bakterien durchsetzt, erscheint. Der Durchmesser diesen hellen Zonen wurde mit der Positiv-Kontrolle {Gentamyzin) derselben Platte korreliert, um ein MaB der antibakteriellen Aktivitat zu erhalten (Abbildung 2). 
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Tisseel®, Tissucol® (Baxter, IL, USA): Entsprechend dem Protokoll des Herstellers wurden die insgesamt 4 Komponenten des kommerziell erhfiltlichen Gewebeklebers auf 37 Grad Celsius erwarmt und zu zwei Kom­ponenten vermischt (Fibrinogen und Thrombin). Bis zur endgiiltigen Mischung beider Teile zum aktiven Fibrin, wurde die o.g. Temperatur fur wenige Minuten beibehalten und in fallender Konzentration erfolgte die Mischung des vorbereiteten Protegrin-1 mit der Thrombinkomponente in entsprechenden Verhfiltnissen (s. Tabelle 1) . Die resultierenden Mischungen wurden erst im ausgestochenen Stanzdefekt des Agars zusammengefiihrt und somit die Fibrinbildung mit PG-1-Inhalt initiiert. Abbildung 2 zeigt den Versuchs­ansatz in unterschiedlichen Mischungsverhfiltnissen der PG-1- und Fibrinkleber-Kompo­nenten auf den Radial-Diffusionsplatten. Das dabei ermittelte, fur die weiteren Versuche adaquate Mischungsverhfiltnis wurde fur die Anwendung in den in vivo Experimenten eingesetzt. 
In vivo Experimente : 
Tierexperiment: Fur die in vitro Experimente wurden mannliche, ausgewachsene Sprague-Dawley-Ratten (n= 15) mit einem Durchschnittsgewicht van 250 Gramm einer 15%igen Verbrennung/ Verbriihung ihrer Korperoberflache unterzogen (Tiefe Ub) und in 3 gleiche Gruppen ran­domisiert. Die Verbrennung wurden entsprechend den Vorgaben des National Institutes of Health (NIH) und der Tierexperimentellen Einrichtung der University of Michigan (ULAM, UCUCA) fur kleine Nager in Allgemeinnarkose mit gewichtsadaptierter Gabe von Ketamin und Xylazin intraperitoneal durchgefilhrt und van der Ethikkomission genehmi­gt. Postoperativ erfolgte die gewichtsadaptierte Analgesie mit Bupivacain (Buprenex®) alle 6-8 Stunden. Die Tiere wurden bis zur volligen Mobilitat iiberwacht, der Fliissigkeits­ersatz erfolgte durch die subkutane Applikation van physiologischer Kochsalzlosung. Die Ermittlung der Verbrennungsflache ergab sich aus der Formel van Meeh [8] . Die Wunden wurden sofort nach der Verbriihung unter sterilen Kautelen mittels lxl06 Pseudomonas aeruginosa inokuliert. Die Pseudomonas-Bakterien waren durch ein Bakteriogramm var den Experimenten als multiresistent (unter anderem Silvadene®/Silbersulfadiazine) ein­gestuft warden. In 3 Gruppen Oe 5 Tiere) wurde entweder topisch ein Gemisch aus Fibrinkleber und Pro­tegrin-1 (PG-1) (50 Volumen % PG-1 ,  Konzentration des PG-1 lOOµg/ml, 50 Volumen % der Thrombin/Fibrinogen-Mischung, 2,5ml pro Applikation), oder ungemischtes, fliissiges PG-1 (2,5 ml, Konzentration: lOOµg/ml, Kontrollgruppe), oder 2,5 ml des Fibrinkleber­gemisches (negative Kontrolle) topisch appliziert. Pro Untersuchungsgruppe wurde die Mischung aus Protegrin mit dem Kleber und die einzelnen Komponenten, zusammen mit den Bakterien unter sterilen okklusiven Verbanden aufgebracht, um Kreuz-Kontaminati-
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onen fiir die Zeit des Versuches zu vermeiden (Abbildung 3). Es wurde hierzu ein steriler 
Tupfer auf das Verbrennungsareal mit den unterschiedlichen Komponenten aufgebracht, 
durch eine Klebefolie (ahnlich einer OP-Folie) verschlossen und eine Manipulation durch 
das Tier ausgeschlossen, indem selbsthaftendes, elastisches Verbandsmaterial uberwi­
ckelt wurde, das die Mobilitat zur Reinigung und Nahrungsaufnahme der Tiere nicht 
beeintrachtigte. 
Nach einer Inkubation uber 24 Stunden wurden Hautbiopsien entnommen, gewogen, ho­
mogenisiert und als Verdunnungsreihe in Triplets auf Schafblutagarplatten aufgebracht 
und uber Nacht inkubiert. Am folgenden Tag wurden die Pseudomonaskulturen Untersu­
cher-geblindet ausgezahlt. Die Bestimmung des Pseudomonaswachstums erfolgte mor­
phologisch anhand der Kulturen. Daraus wurden die Bakterienzahlen pro Gramm Haut 
im Vergleich der drei Gruppen ermittelt (Abbildung 4). 
Abbildung 3. Betaubte Sprague-Dawley Ratte mit okklusivem Verband entsprechend der Versuchsanor­
dnung unter selbstklebendem und elastischem Schutzverband gegen die Manipulation durch das Tier; 
freie Mobilitat mit dem Verband bleibt erhalten 
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Gewebekleber PG-1 + Gewebekleber 
Abbi/dung 4. Reduktion der Keimzahlen in Pseudomonas-infizierten Verbrennungswunden (Hautho­mogenisate). Signifikanter antimikrobieller Effekt bei Vermischung van PG-1 mit Fibrinkleber gegenuber den ungemischten Komponenten (p<0,04 und p<0,01) 
Ergebnisse : 
In vitro Experimente: Im Radial-Diffusionsassay zeigte sich eine von der jeweiligen PG-1 Menge abhangige an­timikrobielle Wirkung des ungemischten PG-1 und der PG-1-Kleber-Gemische (Abbildung 2). Die antimikrobielle Aktivitat des PG-1 wurde durch das Beimischen von Fibrinkleber nicht inaktiviert, sondern proportional zum Verdiinnungsvolumen reduziert. Das in Mi­schung eingebrachte PG-1 zeigte abhangig vom Volumenanteil eine Wachstumshem­mung der in Agar wachsenden E.coli-Bakterien, erkennbar am ,,Hemmhof". Die Zone der Wachstumshemmung (mit Gentamycin als 100%) zeigte eine Verminderung auf 50,7% mit Protegrin-1 allein, auf29,4% mit dem Peptid-Fibrinklebergemisch (Mischungsverhalt­nis 1 :1) , auf 26,3% mit einem Mischungsverhfiltnis von 1 :2 Fibrinkleber zu PG-1 und auf 16,5% mit dem Mischungsverhfiltnis 2 :1 Kleber zu PG-1 (Tabelle 2). Die positive und ne-
Gentamyzin 100% PG-1 50,7% 
Kleber-PGl 1 :1 29,4% 
Mischung Kleber-PGl 1:2 26,3% 
Mischung Kleber-PGl 2:1 16,5% 





gative Kontrolle sind als ,,Proof of concept" des wissenschaftlichen Ansatzes zu werten. 
Es zeigte sich eine maximale bakterielle Inhibition durch das zentral verbrachte Genta­
myzin und keine bakterielle Hemmung durch den reinen Fibrinkleber. Die in vitro-Experi­
mente des Radial-Diffusion-Assay bestatigten somit unseren wissenschaftlichen Ansatz, 
dass die Mischung aus Gewebekleber und Protegrin-1 ebenso wie das antimikrobielle 
Peptid allein eine antibakterielle Wirksamkeit auch gegen einen resistenten Pseudomonas 
aeruginosa Stamm besitzt. 
In vivo Experimente: 
Die Bakterienzahlen in den in vivo Experimenten zeigten keine signifikanten Unter­
schiede im Vergleich der ungemischten Protegrin-1 und Gewebekleber-Gruppen (Abbil­
dung 4) nach der -Obemacht-Inkubation {Gruppe PG-1: 53908 ± 18020 {Kolonien/Gramm 
Hauthomogenisat), p< 0,04; Gruppe Fibrinkleber: 57219 ± 15273, p<0,01; Gruppe PG-1 
plus Fibrinkleber: 7621 ± 3495}. Die Tabelle zeigt die Anzahl der Bakterienkolonien {Mit­
tel aus dreifachem Ansatz) pro Gramm Haut im Vergleich der drei gebildeten Gruppen. 
Die Tiere, welche die Mischung aus dem Gewebekleber und dem PG-1 erhalten hatte, 
zeigten eine signifikante Verminderung der Zahl der Bakterien verglichen mit den beiden 
Kontrollgruppen {p< 0,04 und p<0,01}. Kein Tier verstarb wahrend des Experimentes {s. Abb. 4; Statistik: ,,unpaired means of comparison", StatView®, SAS Inc. USA). Im Vergleich 
beider Kontrollgruppen mit der Mischung aus Kleber und dem antimikrobiellen Peptid, 
ergab sich eine Reduktion der Bakterien auf ca. ein Fiinftel. In unserer Analyse wurde 
keine Kreuz-Kontamination mit anderen Bakterien als Pseudomonaden gesehen. 
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Diskussion : 
Antimikrobielle Peptide sind bereits seit ungefahr 70 Jahren im Tier- und Pflanzenreich 
bekannt [9] .  So besitzt selbst die Drosophila melanogaster die Fahigkeit zu ihrer Produk­
tion. Gewohnlich sind diese Peptide ungefiihr 1 00 Aminosauren lang und werden van 
individuellen Genen codiert, die eine Intron-Exon-Struktur aufweisen [1 0]. Bis heute 
kennt man iiber 500 solcher antimikrobieller Peptide, wobei regelma.Eig neue Beschrei­
bungen publiziert werden (htt_p://www.bbcm.univ.trieste.it/-tossi/antimic.html). Cha­
rakteristischerweise bestehen sie aus hydrophilen und hydrophoben dreidimensionalen 
Strukturen, die es ihnen ermoglichen, durch Einbau in die bekannten Lipidschichten 
der Zellwande ,,Poren" zu formen und durch einen Austausch van extra- und intrazel­
lularen Ionen zum Zelltod zu fiihren (Shai-Matsuzaki-Huang Modell) [1 1,  1 2]. Aktuell wird 
diskutiert, dass der Zellwandaufbau (die Mischung der unterschiedlichen Lipide) einen 
essentiellen EinfluB auf die Effizienz dieser Peptide spielt und zur Unterscheidung zwi­
schen ,,korpereigen" und ,,korperfremd", im Vergleich der Mehrzeller zu den Einzellern 
beitragt. Lymphozyten, Endothelzellen und Keratinozyten produzieren AMPs und geben 
dadurch deutliche Hinweise auf deren Wichtigkeit zum Schutz der endothelialen wie der 
epithelialen Oberflachen der Lunge, der Haut und des Gastrointestinaltraktes [ 13, 14]. Im 
Menschen finden sich Defensine, Cathelizidine (wie Protegrin-1, LL37 usw.) und Histatine 
[1 0] .  Wenn man nach einem ,,Mangelsyndrom" der AMPs als Ursache van Erkrankungen 
oder moglichen Hinweisen auf die Pathogenese dieser Erkrankungen sucht, so ergeben 
sich Verbindungen zum Chediak-Higashi-Syndrom, zur zystischen Fibrose und Einfliisse 
bei genereller Immundefizienz [2, 1 5]. Diesem postulierten Mangel steht die genetisch 
nachweisbare ,,up-regulation" durch die Anwesenheit und Stimulation van Lipopolysac­
charid, LPS (Synonym filr ,,Endotoxin" und entspricht dem wesentlichen Bestandteil von 
Gram-negativen Bakterienwanden), Interleukin 6 und retinoischer Saure gegeniiber. 
Protegrin-1 (PG-1, Abbildung 1), ein Vertreter der antimikrobiellen Peptide das urspriing­
lich aus Schweine-Neutrophilen isoliert wurde, konnte in Vorexperimenten unseres La­
bors die bakterielle Infektionsrate in einem Rattenverbrennungsmodell deutlich reduzie­
ren [1 6] .  Andere Untersucher konnten in ihren Tiermodellen zeigen, dass sich einerseits 
die Uberlebensrate durch die topische Anwendung der Peptide in Verbrennungen drama­
tisch steigem lief?, [1 7], in einem anderen Fall wurde die Menge eines Oberflachenpeptids 
(humanes Beta-Defensin) in brochoalveolaren Lavagen von Patienten mit Verbrennungen 
im Vergleich zu einer Kontrollgruppe untersucht [1 8]. Auch hier zeigten sich erhohte 
Werte bei Verbrennungspatienten, ein Hinweis filr die vermehrte Produktion durch das 
Verbrennungstrauma. In einem weiteren Versuch konnte gezeigt werden, dass in Ver­




Chapter 5 lagen und korrelierten [19] ,  bei zweitgradigen Verbrennungen verlagerten sich die Pro­duktionsstatten der Peptide aus der Dermis in deren Anhangsel wie Haarfollikel oder SchweiBdriisen. Die Wirkung der Peptide ist demnach nicht nur einem einzigen Peptid zuzuordnen. Im Gegensatz zu unserem Verbrennungsmodell verwenden die meisten Un­tersucher derzeit drittgradige Verbrennungen, ausgenommen Milner et al (19] . Verbrennungen bis zur Tiefe IIB sind Gegenstand unseres Interesses, da sich die Frage stellt, ob bei tiefdermalen Verbrennungen der Organismus in der Lage ist, das infizierte Wundmilieu bei verlorengegangener Schutzschicht der Haut <lurch die ortstandige Ab­wehr des angeborenen Immunsystems zu kompensieren und wie die lokalen Defen­sivstrategien gegen eindringende Krank:heitserreger aussehen. In mehreren Versuchen der klinischen Umsetzung der attraktiven Potenz antimikrobieller Peptide werden zur Zeit Phase II und III Tests durchgefiihrt [2] , die sich allerdings aufThemen wie den diabe­tischen FuB und <lessen komplizierende Ulzerationen, sowie die orale Mukositis [20] und das Beschichten von intravenosen Dauerkathetern konzentrieren. Die Erforschung im Rahmen von Verbrennungen wird derzeit nur von wenigen inter­nationalen Forschergruppen vorgenommen. Entsprechend unserem Forschungs-schwer­punkt, wurde nach Etablierung eines standardisierten Verbrennungsmodelles an kleinen Nagern, Untersuchungen zur Wirkung der lokale Applikation von Protegrin-1 (PG-1) in infizierten Verbrennungen der Tiefe IIB durchgefiihrt. Es sollte die biologische Aktivitat und Wirkung von einem Gemisch aus Fibrinkleber mit PG-1 gegen einen multiresistenten Stamm Pseudomonas aeruginosa nach Vorversuchen in vitro und in vivo bestimmt werden. Das in fliissiger Form vorliegende aktive Peptid stellte eine Herausforderung im Handling dar. Ein Losungsansatz ergab sich durch die Kombination mit Gewebekleber, um nun­mehr einfachere Anwendbarkeit, die Problematik der Applikation auf unebenen Oberfla­chen und die gewiinschte topische antibakterielle Aktivitat moglichst optimal verbinden zu konnen. In aus der Literatur bekannten Studien war die Umsetzung der Idee topischer antibakteriell wirksamer Substanzen in mehreren Studien vorbeschrieben [3-5, 21-23] . Nach einer Serie von in vitro-Versuchen mit unterschiedlichen Konzentrations- und Mi­schungsverhaltnissen, in enger Anlehnung an die Richtlinien zur Verwendung des Ge­webeklebers, zeigte sich die mogliche klinische Anwendbarkeit, indem das verwendete Peptid nicht durch den Kleber in seiner antibakteriellen Wirkung neutralisiert wurde. Zudem erleichterte sich das Aufbringen des Protegrins in vivo durch den Kleber. Die Ergebnisse unserer Tierstudien erklaren sich auch durch die Art der Applikation ei­nerseits als fllissiges Medium des puren Peptids, andererseits des Klebergemisches plus Peptid. ErwartungsgemaB sollten die Bakterien <lurch das ,,pure", unvermischte Prote­grin-1 deutlich reduziert werden, allerdings ist die Zahl der Bakterienkolonien ahnlich hoch wie in der Gruppe der nur mit dem Kleber ,,behandelten" Tiere. Eine mogliche Erkla­rung ist die zunehmende Kontaktzeit des Peptids zusammen mit dem Kleber, der in nur fliissiger Form leicht von der Rattenhaut abtropft: und durch Aufnahme in den sterilen 
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Verband an Wirkung zu verlieren scheint. Im Gegensatz dazu ist durch das Mischen mit 
dem Kleber ein Film aus Kleber-Peptid-Gemisch auf der Haut prasent, der dort seine an­
tibakterielle Effizienz lokal verbreiten kann, ein Effekt der durch den Kleber allein nicht 
auftritt. Es ist bekannt, dass die Peptide ca. 6 Stunden Wirksamkeit aufweisen, bevor das 
bakterielle Wachstum wieder in Gang kommt und die zuvor erzielte Keimzahlreduktion 
bald wieder zunichte macht. Der Organismus schaffl: dies durch standige Neuprodukti­
on und Mischung verschiedener Klassen von AMPs im klinischen Bedarfsfall. In unseren 
Experimenten wurde einmalig extern Protegrin-1 hinzugefiigt, jedoch nicht kontinuier­
lich, weshalb die Reduktion der Krankheitserreger als nur kurzfristig gesehen werden 
darf. Dennoch bietet dieser Effekt neben dem Vorteil der bisher nicht und als extrem 
unwahrscheinlich einzustufenden Resistenzentwicklung, noch den Zeitgewinn in der Ko­
lonialisation und Infektion, sowie die breite Wirksamkeit gegen die eingangs erwahnten 
Gram-negativen und Gram-positiven Bakterien, spezielle Pilze und je nach Aufbau der 
externen Membranen, auch pathogenen Viren. Diese Pluripotenz stehen im Experiment 
die Produktionskosten gegeniiber. 
Schlussfolgerung : 
Wir konnten in unseren Studien zeigen, dass die Applikation eines Gemisches aus Pro­
tegrin-1 (einem kommerziell erhfiltlichen antimikrobiellen Peptid) und einem kommer­
ziell erhfiltlichen Gewebekleber die bakterielle Keimbesiedelung in Verbrennungswun­
den signifikant zu reduzieren vermochte. Beide Komponenten erwiesen sich in unseren 
Handen als stabil und deaktivierten sich nicht gegenseitig. Eine Behandlung im Rahmen 
der klinischen Umsetzung an Verbrennungspatienten konnte kombiniert mit Hauttrans­
plantaten und kiinstlichem Hautersatz Verwendung finden, um in der im Outcome so 
wichtigen Friihphase nach Trauma eine topische Unterstiitzung im Kampf gegen Krank­
heitserreger bereitzustellen. Weitere Anwendungsbereiche auF.,erhalb der Verbrennungs­
medizin sind denkbar. Erganzende, vor allem aber klinische Studien !assen weitergehende 
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Infected burn wounds pose a source of high morbidity and mortality, and within infec­
tions, Gram-negative ones cause more serious problems than Gram-positives. The way by 
which living bacteria in a per se problematic deep partial thiclmess burn wound have an 
impact on the innate immune system remains rather unclear. Therefore, the goal of the 
research described in this thesis, was to shed more light onto the interaction of parts of 
the innate immune system with invading Gram-negative bacteria in deep partial thick­
ness burns in vivo and the role of LBP in this and to investigate potential new therapeutic 
approaches to counteract Gram negative infections of burn wounds. 
Lipopolysaccharide binding protein (LBP) is believed to play a key role in repelling invad­
ing Gram-negative bacteria as described in bacterial peritonitis in the past, and in initiat­
ing the host's immune response. We were therefore interested in the topical and systemic 
innate immune response generated by invading Gram-negative bacteria represented by a 
multiresistant Pseudomonas aeruginosa that was the source of delivering lipopolysaccha­
ride (LPS) to the wound. The resulting LBP-LPS binding, mediated by several proteins such 
as membrane-bound and soluble DCl 4 and the Toll-like receptors, is believed to initiate 
the production of pro- and anti-inflammatory cytokines moderating the host , s mecha­
nisms of defense. By means of IBP-knockout mice the unique opportunity was given to 
gain more insight into the innate immune system lacking the capacity of producing LBP 
in response to burn wound infliction, even without introducing a standardized infection. 
We furthermore designed an adenoviral construct encoding for LBP that was used for 
gene transfer studies to analyze the effect of LBP rescue in LBP lmockout (LBPko) mice, 
respectively overexpression in wild type (wt) mice. Therewith we could possibly identify 
its potential as gene therapy tool for future application in burn wound treatment. 
Recently, antimicrobial peptides were reported to play a crucial, but poorly understood 
and sometimes contradictory role in innate immunity. These peptides are usually pro­
duced following a 'supply and demand' situation by the organism in a state of inflam­
mation or infection. Since they represent a new class of antimicrobial agents targeting 
bacteria at their outer cell wall composition with broad Gram-positive, Gram-negative 
and fungal activity, we were interested in integrating these newly found and promising 
peptides into our studies on burn wound infection treatment. 
With regard to the clinical problems associated with infected burns potentially leading to 
high morbidity and mortality, a set of experiments was designed to address the following 
research aims: 
1) To develop an in vivo, deep partial thickness {IIB} bum wound model in mice and apply 
this to both a new LBP-knockout mouse model and its corresponding wild type control; 
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2) To gain more insight into the ability of LBP to reduce the number of living, multiresistant, 
Gram-negative bacteria in deep partial thickness {IIB) bum wounds with special regards 
to innate immunity; 
3) To apply an adenoviral construct encoding LBP as a tool to study whether this intradermal 
adenoviral gene delivery system represents a feasible therapeutic approach to bacterial 
infected bums; 
4) To test the ability of a new class of antimicrobial agents {AMPs} capable of reducing the 
number of bacteria in our deep partial thickness bum wound model. First, an in vivo bum wound model had to be established, enabling us to design and execute experiments aimed at gaining more insight into the complex immunological mechanisms occurring in type IIB, infected partial thickness bums. Since our lab had an LBP-knockout mouse colony available, whose feature was the inability to produce LBP, the first aim was to compare the ability of this colony to defend the host against standardized Gram-negative infections and compare this to wild type controls. For this purpose, we inflicted a defined bum wound to both animal groups. The bum itself was designed to feature a living, thus regenerating wound bottom, clinically defined as class IIB that struggles with the restoration of missing dermal structures per se. As learned from devastating patient courses on intensive-care burn units, IIB-bum wounds become even more deleterious when infected. Based upon the fact that some bacteria such as Pseudomonas aeruginosa hide in biofilm formations, thus making wound clear­ance even more difficult, we deliberately chose to culture a live, and above all, multire­
sistant Pseudomonas aeruginosa strain to be used in all our experiments. Pseudomonas 
aeruginosa continues to be one of the most problematic bacterias in bum wound care. In chapter 2 we described the design of the experimental set-up, consisting of the mouse colonies and bum wound challenge with standardized Gram-negative infection. At first, we were interested in finding out whether there were differences in Pseudomonas growth on bum wounds in either of the two mouse colonies. As a result, we did not find differ­ences in bacterial growth, neither in knockout nor in wild-type mice. In order to study whether overexpression of LBP, either in wt or in LBP k.o. mice plays a key role in innate immunity in infected partial thickness bums, we designed an adenoviral construct en­coding LBP. We showed that the LBP encoding virus was capable of inducing LBP protein expression in in vitro cell systems. Immunohistochemically studying b-gal staining in the skin of mice locally treated with the adenovirus encoding �gal as control viral construct, next demonstrated feasibility of transgene expression in vivo using this gene transfer system. By restoring LBP intradermally in otherwise IBP-deficient and by over express-
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ing in wild type animals, we could confirm our hypothesis that this protein is impor­
tant in Gram-negative infection, demonstrated by the reduction of Pseudomonas bacterial 
numbers. Restoring LBP in LBP-deficient mice led to a reduction of bacterial numbers 
by 44-fold, and over-expressing this protein in wt animals led to a reduction of 4.9-fold. 
Furthermore, we showed that adenoviral LBP gene therapy in infected partial thiclmess 
burns in rodents was feasible. 
In chapter 3, we focused in more detail on the intradermal alterations occurring in an or­
ganism lacking LBP protein. We were specifically interested in the transcriptional chang­
es taking place at the site of injury, and therefore compared intradermal gene expression 
profiles following burns in either mouse strain. Commercially available microarray-chips 
were used for this purpose. Eighteen-hundred-and-two genes were at least two times 
up- or down-regulated in lmockout animals compared to wild-types. The most extensive 
up-regulation occurred in growth-related oncogene-1 (GR0-1 ), a CXC-chemokine known 
for its capacity of neutrophil chemoattraction in rodents. Neutrophils are key cells in or­
chestrating the immune response. In our model, GR0-1 was up-regulated intradermally 
53-fold in LBP-knockout mice at six hours post-burn. Along with this neutrophil chemoat­
tractant GR0-1, changes in pro- and anti-inflammatory cytokine gene expression were 
of interest. Since the effector cells of GR0-1 protein are neutrophils, we conducted a 
quantitative analysis of peripheral leukocytes and their subsets in IBP-knockouts versus 
wild-types, first in uninjured animals. This analysis revealed no significant difference 
in the total number of peripheral white blood cells and their subsets between the two 
when unharmed. We repeated the blood analysis at 24 hours following the type IIB-burn 
in both animal groups. In LBP-lmockouts, the total peripheral white blood cell counts, as 
well as the numbers of neutrophils and lymphocytes detected, increased significantly at 
24 hrs, compared to the baseline reading at an uninjured state. In wild-types, in contrast, 
the total white blood cell counts, along with neutrophils and lymphocytes, were not 
significantly affected, as opposed to monocytes which showed an increase at 24 hours 
in type IIB burn compared to their levels at an uninjured state. We next aimed to deter­
mine the expression of GR0-1 along with those of other pro- and anti-inflammatory cy­
tokines using quantitative reverse-transcription polymerase chain-reaction (qRT-PCR) at 
24 hours. At this later time point, GR0-1 was less extensively expressed in knockout skin 
than in wt skin, while the other cytokines studied, i.e., IL-6, TNFa and IL-10, showed no 
significant difference between the two groups at 24 hours. 
To gain further information about the role of the neutrophil in the processes under study 
and to follow up on the changes in expression profile in time described in chapter 3, we 
expanded the timeline of our study on cell and chemo-/cytokine behavior to 96 hours 
(chapter 4). Of the cytokines studied, GR0-1, TNFa and IL-10, showed a biphasic expres-
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sion, meaning an increase at 24 hours after the injury compared to 6 hours, decreasing 
at 48 hours and increasing again at 96 hours in both animal groups. In contrast, IL-6 
showed a monophasic profile, with almost 10-fold lower expression levels in knockout 
mice in the later time points, whereas TNFa and IL-10 did not show significance between 
the groups. With regard to deciphering a possible relation between GR0-1 regulation in 
time and neutrophil behavior in our experimental set up, we studied neutrophils intra­
dermally and in the peripheral white blood cell pool. Peripheral neutrophil numbers over 
the time-course between 24 and 96 hours remained unchanged in LBP-knockout mice, in 
contrast to those in the wild types, which showed a peak at 48 hours. 96 hours post bum, 
LBPko mice had almost doubled their total WBC numbers in peripheral blood, and dem­
onstrated lyrnphocytosis, whereas knockout mice had less monocytes at 48 hours after 
bum. In order to study neutrophil distribution in the skin, we applied a myeloperoxidase 
(MPO) assay at 24, 48 and 96 hours. Every time point showed higher MPO-levels in wild 
type skin, suggesting larger numbers and/or higher activation of intradermal neutrophils 
in wild type mice. The neutrophil numbers or their intradermal activation could not be 
associated with the intradermal GR0-1 expression kinetics found earlier. 
Since LBP has proven importance in defined bacterial infections in our bum model, we 
were interested in the natural bacterial colonization of the healing skin following a type 
IIB bum in knockouts and wild types. This condition was created by leaving the burn 
wound uncovered, thus without any occlusive dressing, and without defined bacterial 
infection. At 6 days post trauma, there were more bacteria on wild-type skin than on 
knockout, and that the colonies were for the most part Gram-positive. Lack of LBP obvi­
ously changes the organisms' topical capacity of defending infections arising in a bum 
model leading us to conclude that there might be a compensatory immunological mecha­
nisms, the nature of which is currently unknown, compensating for the absence of LBP. 
Regarding increasing problems with multi-drug resistant bacteria, an ancient part of the 
innate immune system has drawn more and more attention in the last 10 to 15 years. An­
timicrobial peptides (AMPs) are known in plants, cold-blooded animals and vertebrae as 
well as humans. Their potential use in a clinically applicable formulation was the subject 
of our research described in chapter 5. AMPs represent ancient weapons, triggered by 
infection and inflammation. These peptides target invading bacteria, viruses and fungi 
as long as they are coated by lipid layers as their outer cell walls, and they also seem to 
participate in orchestrating immune responses. AMPs therefore seem to play a key role 
in innate immunity. We hypothesized that such peptides may be advantageous in the 
treatment of bum wound infections. To test our hypothesis, an antimicrobial peptide 
of 18 amino-acids in length was produced, called Protegrin-1 (PG-1). It's in vitro efficacy 
was tested first by means of a radial diffusion assay against the Pseudomonas strain we 
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used for all our experiments. We showed that the bacteriotoxic effect was concentration­
dependent, and that the effect did not fade when mixing the peptide with a commer­
cially available fibrin sealant. The necessity of mixing these two components was born 
out of practical handling problems, since the dissolved bioactive peptide had a watery 
consistency and simply would drip from the burn wounds without staying long enough 
to deliver its antibacterial effect. We next applied this formulation in in vivo studies onto 
our standardized, infected burn wounds. Substantial decrease of multi-drug resistant Pseudomonas colonies in partial thickness burns was observed. Concluding, we successfully developed a mouse bum-wound model grade IIB, and ap­
plied it to a mouse colony which lacks the ability of producing LBP, important in defend­
ing Gram-negative infections, and their wild type controls. With this model, we demon­
strated that absence of LBP in knockout animals per se did not hamper a proper defense 
response against infection at the burn wound site. An adenoviral construct encoding LBP 
reduced the bacterial numbers in knockouts and wt mice significantly, by topically either 
restoring or overexpressing this protein. Intradermal gene-chip analysis and gene ex­
pression profiles demonstrated profoundly altered pro- and anti-inflammatory cytokine 
expression profiles at various time points following burn in the absence of LBP protein 
synthesis capacity. The chemokine GR0-1 was found to be intradermally up-regulated 
in knockout animals at an early time point. As GR0-1 is considered a major attractant 
for neutrophils, we next studied leukocyte and leukocyte subsets in peripheral blood, 
revealing different cellular immune reactions in mice lacking LBP and having received a 
25% total body-surface partial thickness burn. However, no higher neutrophil numbers 
or neutrophil activation was found in knockout animals systemically or locally at the site 
of burn. Knockout animals had less topical bacteria when we observed natural dermal 
re-colonialisation showing Gram-positive bacteria 6 days after burn. This led us to the 
condusion, that there potentially is a compensatory immunological mechanism in the 
absence of LBP. By the application of Protegrin-1 as a model antimicrobial peptide, mixed 
with fibrin glue, we were able to demonstrate its efficacy of reducing Pseudomonas bac­
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Future perspectives Based on our findings during the course of these experiments, several conclusions sug­gest further research in the field of innate immunity and burn wound infections. Intensive care problems such as ventilator-associated infections, nosocomial wound in­fections, the general topic of sterility, antibiotic-induced bacterial selection, questions of bum-induced hypermetabolism, compromised host defense as a consequence of severe bum injury, general immunodepletion, the correct timing of surgical interventions and the like, make intensive care in bum units highly dynamic, sometimes poorly predictable, but always challenging. In the struggle for the best possible treatment, intensivists and surgeons need to be closely collaborating. Critical decisions must be taken on a daily ba­sis, and often therapeutic regimes need to be adopted to the patient ' s  needs and rapid changes. Currently, severe bum patients remain at high risk for local and systemic infec­tions, responsible for the main cause of death among these patients (1, 2). 
Future perspectives of burn wound infections : Worrisome reports of multi-drug resistant pathogens, such as Staphylococcus aureus, Pseu­domonas aeruginosa, Acinetobacter spp., as well as various resistant fungal strains, raise concerns with regards to bum victims and are causes of high morbidity and mortality within this group (3). Over the last years, not only multi-resistance and pre se trouble­some Gram-negative infections are feared for in serious bum wound infections, but also polymicrobial infections, such as combinations of Gram-positive, Gram-negative bacteria and fungi, pose increasing, serious threats (4-6). Next to bacteria, rising numbers of fungi found in bums contribute to the often deleterious consequences of these problematic wounds (7). A weakened, immune-compromised host following severe bum marks the predisposition, where opportunistic pathogens such as Staphylococcus aureus, Enterococ­cus f aecalis and Pseudomonas aeruginosa transform into potentially deadly microorgan­isms (8). Worldwide, a debate is ongoing about the fact, that there seem to be regional differences regarding definitions of 'THE major pathogen' responsible for bum wound infection, and ultimately morbidity and mortality. Multinational, comparative epidemiologic studies are still missing (9) to shed more light onto this problem. In a recent survey of 104 U.S. bum units with 44% of the centers responding (3), P. aeruginosa was still identified as the most prevalent Gram-negative pathogen, followed by Acinetobacter baumannii and Enterococcus spp. (10). In Asia the picture is slightly different, where A baumannii and Proteus mirabilis are found to be the most common causes of bum infection, with Pseu­domonas aeruginosa presenting itself in third place (3). In Europe, however, P. aeruginosa next to Escherichia coli remain the two most common pathogens found on bum wounds, each responsible for 13% of all Gram-negative infections (11). Given that these studies 
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Chapter 6.2 were rather recently published, these data need to be accepted as currently valid, as opposed to data from 15 or 20 years ago, when discussing 'regional differences' of burn wound infections and possible therapeutic consequences. At first, in every burn unit, the most problematic and most prevalent pathogen needs to be identified and there­with its source. Having accomplished this step, eradication and prophylaxis protocols need to be set up. Since burn units are places where moist, warm climate conditions are required, Pseudomonas aeruginosa finds almost ideal growth conditions. We deliberately chose this bacterium in all our experiments for obvious reasons, as Pseudomonas was and still is a serious threat for wound infections on burn patients. There is a constant need for improvement in wound dressings, sterility, mandatory intravenous ports, ventila­tor equipment, and wound care products thriving to induce re-epithelialization, to keep the chance of bacterial infection and/or fungal super-infection as low as possible until wounds are closed and epithelialized. New antibiotic drugs, new treatment standards, new bioactive coatings of catheters, repellent surfaces of implants capable of stimulating ingrowth but repelling pathogens etc., remain challenges for researchers and industry. Better understanding of results derived from research projects such as ours, form the basis of interventional strategies to help conquer or even prevent burn wound infections. Antimicrobial peptides might help in these clinical problems, as discussed here. 
Future perspectives of 'the neutrophi l '  i n  burns :  With the skin as the first line of defense gone, the organism has to rely on the innate im­mune system to face any invading pathogen. In conditions such as burns, macrophages and neutrophils typically orchestrate the immune response and mediate innate and adap­tive immunity. Several studies have confirmed that as a consequence of thermal injury alone, neutrophil chemotaxis is compromised (12-18}. In our research, the neutrophil was of high interest, since GRO-1, the murine neutrophil chemo-attractant and equivalent to human IL-8, was strikingly up-regulated in the skin of burned LBP-knockout mice. There are differences in the generation of neutrophil data, since some publications use animal, others human studies, making comparability questionable especially when deal­ing with complex and highly dynamic immunological scenarios such as wound infections and host responses. One has to decipher clearly between murine- and human-derived findings and care must be taken when it comes to interpretation. Neutrophils and their subpopulations, as well as macrophages are no exception in this regard. Interestingly, two subtypes of murine neutrophils seem to play a role in the activation of two subtypes of macrophages. The activation is triggered by neutrophils releasing IL-10 and CCL2 (che­mokine ligand-2, also known as monocyte chemotactic protein-I (MCP-1))(19} .  In 2004, Tsuda and co-workers published that murine neutrophils (PMNs} differentiated into sev­eral subtypes (PMN I, PMN II and PMN-N}, each responsible for different tasks (20). Neu-104 




On a ntim icrobia l peptides : 
As stated before, antimicrobial peptides {AMPs} are ancient weapons, part of the innate 
immune system, and possess broad antimicrobial activity against Gram-positive and 
Gram-negative bacteria, fungi and viruses (23-26} . According to the Shai-Matsuzaki-Huang model (25, 27-29}, by lipid-protein interaction of the outer cell wall with the antimicrobial 
peptide, pores are formed within the cell wall allowing intra-extracellular ion-transit and 
thus cell death. Recent information points at the importance of physiologic salt concen­
tration being a factor with direct impact on AMP activity (30}. 
Skin-derived AMPs are more than simple 'naturally occurring antibiotics', because they 
can also trigger chemotaxis, as well as angiogenesis, cell proliferation, and the produc­
tion and release of cytokines, chemokines and inflammatory mediators, which are impor­
tant features in the pathogenesis of skin diseases (30} and host defense. These microbici­
dal activities together with their immune modulating properties make AMPs interesting 
candidates for the development of novel therapeutic agents. Unfortunately, at the mo­
ment, there is not enough knowledge on how exactly they orchestrate the innate and 
adaptive immune system and how, for instance, the intracellular pathways of secondary 
messengers in immunocompetent cells are initiated. Therefore, stimuli and effectors are 
currently not fully understood. 
If not replaced or produced, AMPs' biological effects last only briefly. In the clinic, there 
are situations where a short acting antibiotic effect is actually wanted, such as when us­
ing implants. Here, only short-term protection is needed, namely, when contamination 
is imminent or unavoidable, like for instance when skin inevitably touches an implant 
during placement. This is, for instance, regularly the case with silicone breast implants 
which are pushed through a small skin incision into the underlying tissue pocket, poten­
tially leading to acute, sub-acute or slow implant-related infections. Over time, several 
vendors have consequently propagated coatings for silicone breast implants expressing 
advantages in ingrowth and antibacterial properties. At the moment intense research is 
conducted to improve antimicrobial properties of the implant-tissue layer, including in 
the field of plastic surgery, orthopedics, oro-maxillofacial surgery, ophthalmology and 
dermatology. One idea would be to enhance the bacterial clearance at the implant · s in­
terface by use of AMPs, where currently a multi-disciplinary workgroup is set-up at UMCG 
in which the author of this thesis participates. 
With regards to bum-wound infection as in our experimental setup, several researchers 
have reported beneficial effects brought about by these peptides (31-35}. Earlier it was 
described that the concentration of antimicrobial peptides was reduced in tissues sur­
rounding burn wounds, being in part responsible for the impaired host resistance against Pseudomonas aeruginosa (36}. Interestingly, when the antimicrobial peptide-production in 
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a rodent infection model with Pseudomonas aeru.ginosa was pharmacologically enhanced, 
infection was less severe (22). 
There are several scenarios imaginable to improve the effect of antimicrobial peptides in 
infected bums. Firstly, these peptides could be used topically and be mixed with a fibrin 
sealant (37), such as in our studies, avoiding repetitive use and thus potential side effects. 
Secondly, since sometimes vital intravenous lines need to be placed in or close to bum 
areas, it is of utmost importance to keep them as sterile and as resistant against biofilm 
formation and bacterial ingrowth along the catheter as possible. It would make sense to 
protect such a vital device that needs to penetrate the skin and tissues to be placed intra­
venously by a layer of an antimicrobial agent. Thirdly, to prevent fluid loss and loss of pro­
teins together with mechanical stress shielding, dermal substitutes could be equipped 
with such AMPs, again acting topically and making replacement easy, in case they lose 
antibacterial potency or microbial adoption / resistance occurs. Given their advantage of 
broad antibacterial potency, these coatings do not need to be made according to the anti­
bacterial spectrum targeted at, thus affecting Gram-positive and Gram-negative bacteria 
as well as fungi at the same time. Fourthly, the most sophisticated way of enhancing 
topical resistance would be to stimulate the local sources that produce these peptides 'on 
demand', as demonstrated by Yoshida et al who used Glycyrrhizin (22). 
However, certain issues need to be addressed before these potentially new agents can be 
used in the clinic. For example, the signal transduction pathways by which these mole­
cules contribute to both innate and adaptive immunity are not completely unraveled yet, 
therewith it is impossible to rule out any side-effects. The link between the innate and 
adaptive immune system in which AMPs play a role is currently unclear. Furthermore, in 
contrast to preliminary reports, it seems that there are resistances possible to topically 
administered AMPs, demonstrating that excessive use may lead to contrary effects (38). 
As AMPs also manifest diverse biological functions beyond microbial killing, their admin­
istration should be wisely regulated to avoid detrimental effects on host homeostasis 
(30). There are other potential issues to be thought of, including cytotoxicity (39, 40), 
skeletal muscle degeneration (41), possible tumor proliferation (42), possible rosacea 
(43), and chronic inflammation associated with their use. The antimicrobial peptide (ta) 
Lactoferrin is currently being investigated as an anticancer drug in clinical trials (44, 45), 
but seems to play a role in inducing anemia and is associated with renal cell carcinoma 
(46), as well as increasing bone formation systemically (47), hence limiting its use. Next 
to all these possible drawbacks, antimicrobial peptides are still quite expensive to make, 
and have a short life-span. 
Regardless their potential disadvantages, AMPs present themselves with a lot of advan­
tages. First and foremost, they are broadly acting against a wide variety of pathogens 
and they are only produced following a 'supply and demand' pattern, topically or sys-
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temically. They seem to take part in orchestrating the immune response against invading 
pathogens. If their production can be stimulated or their down-regulation be blocked, 
the benefit seems obvious. Currently however, the system of AMPs interacting with the 
innate and adaptive immune system, of which they are an integral part, needs to be 
investigated further before they can be widely applicable as new antimicrobial drugs. 
On LBP, shock and sepsis : 
According to our experimental design, we focused on investigating more thoroughly 
the importance of LBP in Gram-negative infections in burns. Since then, the picture of 
LBP and the role of this protein in Gram-negative infection has evolved in more detail. 
Evaluating Gram-negative infections in LBP-knockout mice by means of an adenoviral 
construct was proven to be valid by Hemmila et al (48}. Here, a systemic gene therapy 
approach is presented in LBP-knockout mice compared to wild-types, in a Gram-negative 
pneumonia model. It was found that the otherwise high lethality in knockouts could be 
reversed by systemic LBP-adenoviral gene therapy. In more detail, the authors showed 
that the cellular response of the host to LPS is mediated through stepwise interactions 
involving LBP, soluble and membrane-bound CD14, and MD-2, which facilitated the rear­
rangement of TIR4 transmitting the signal intracellularely (49}. 
A fact which is interesting in the detoxification process of LPS is it's link to lipoproteins, 
in other words, the fat-metabolism. LBP catalyzes the transfer of LPS into lipoproteins, 
thereby enhancing LPS detoxification (50, 51}. During an acute-phase response to endo­
toxemia, a dramatic increase in circulating LBP is seen (52}. At least in part, LBP is inter­
acting with apolipoprotein-B and binding to LDL, and VLDL, enhancing the LPS-binding 
capacity of these lipoproteins, and serving as protection from the effects of LPS toxicity as 
such (50}, integrating circulating LPS into the LDL/VLDL fraction (50, 53-55}. LDL and VLDL 
form complexes with LPS and therefore imply an important role in the defense against 
bacteria and endotoxin (50}, acting as buffers of LPS. Therefore, during infection, lipid 
metabolism is part of the defense mechanism as it neutralizes endotoxin (LPS} as well as 
viruses (56}. Protection by lipoproteins from LPS toxicity was demonstrated in vivo and in 
vitro (55, 57-59} and binding of LPS to lipoproteins has been demonstrated before (60-62). 
Coupling LPS to lipoproteins reduces LPS toxicity (63}, supported by the fact that hypo­
lipidemia in animals result in higher LPS-induced lethality (55}, and in humans low cho­
lesterol levels predict an increased risk of death from infection (64}. New data on plasma 
phospholipid-transfer protein (PLTP} suggests that increasing circulating levels decrease 
lethality in LPS-induced sepsis and shock in rodents (49}. PLTP is shown to modulate the 
lipoprotein association and metabolism of LPS (65). Furthermore, it seems to play a cru­
cial role in development of atherosclerosis by controlling plasma HDL levels (66} known 
to contribute to this common disease. HDL is shown to bind and neutralize LPS in the 
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course of inflammation and sepsis (67), making it a possible target of immunomodula­
tion. 
Less (or absent) circulating peripheral LBP, as in the knockout mouse-model, means that 
LPS needs to be 'detoxified' elsewhere, for instance in the lipoprotein pathway as de­
scribed above. As a consequence higher rates of atherosclerosis should be seen in LBP­
deficient mice potentially leading to atherosclerosis-related diseases. Further studies 
testing this hypothesis could be executed in LBPko mice, possibly with atherosclerosis 
inducing diets. 
On the dua l  role of LBP, the concentration-dependent effects 
of LBP, CD1 4, and MD-2 : 
Current research puts LPS recognition and binding to LBP, as well as binding to its an­
chors such as membrane-bound or soluble receptors such as CD14 (68), in a different 
light. According to Gioannini and other researchers (69, 70), LBP acts in a dose dependent 
manner in vitro and in rodent studies (71). In high concentrations for instance, LBP is 
thought to be capable of binding LPS and triggering intracellular secondary messengers 
by bypassing the initiating complex (MD-2/TLR4) (72), which it does not do in low con­
centrations. This feature is called the 'dual role' of LBP and CD14. Activation of the organ­
ism by LPS therefore occurs at low concentrations as found in tissues, while inhibition 
of cell activation takes place at high concentrations, as present in plasma. Of note, the 
LPS receptor-activation sequence is enabled by LBP, CD14 and MD-2, but can also be in­
hibited exactly by those three proteins in a concentration dependent manner (71). At low 
levels, LBP can catalyze the transfer of LPS to CD14. Tobias and coworkers (73) reported 
that a selective blockade of CD14 is possible, thereby preventing activation. At higher 
concentrations, LBP aids in clearing LPS aggregates via a non-activating cellular pathway 
(72, 74, 75) and may interfere with LPS transfer from membrane-bound CD14 (mCD14) to 
MD-2 (76). Numerous plasma proteins are furthermore known to bind LPS and therefore 
prevent its coupling to MD-2/TLR4 (77). These include collectins (78), anti-endotoxin anti­
bodies, and the neutrophil granule proteins bactericidal permeability increasing protein 
(BPI) (79), Lactoferrin (80), CAP18 (81) and lysozyme (82), as well as tissue factor pathway 
inhibitor (83). 
Since there is no control over the actual LPS concentration that was administered through 
bum wound infection in the course of our mouse experiments, we have no way of judg­
ing whether the LPS-LBP interaction occurred at low or high concentrations, unfortu­




fortunately, we have no information about the LBP concentration of our wt mice during 
the course of our experiments, which would help in better understanding the LBP effect. 
Whenever we compare research data to clinical data, it is of the highest importance that 
the model used resembles the clinical scenarios as closely as possible. In research, repro­
ducibility and comparability within the experimental setup are of importance as well. In 
all our experiments, we used age and weight-matched female mice. This made a com­
parison between the mouse populations possible, but it neglects the fact that there were 
no data generated in males. For adequate research data dealing with infection, inflamma­
tion, survival and morbidity (as discussed earlier), the model used should be matched in 
male and female, since there seems to be a gender difference as for instance in survival 
and sepsis (84-86), with better odds on the female side. 
In summary, we have shown LBP's potential in reducing bacterial numbers in standard­
ized, infected partial thickness burns. We furthermore showed that the absence of the po­
tential to produce LBP has an effect on chemokine and cytokine production intradermally 
resulting from burns, and on cellular leukocytes and leukocyte subsets thereby altering 
topical immunity. Lastly, we demonstrated that the application of antimicrobial peptides 
in infected burns is possible. A number of important questions have been raised that 
remain to be answered with regard to the complexity of innate immunity and the role of 
LBP in these processes, the role of neutrophils in LBP-knockouts in response to burn, and 
of LBP on Gram-negative as well as Gram-positive infections in partial thickness burns. 
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Ge'infecteerde brandwonden gaan gepaard met een hoge morbiditeit en mortaliteit. Wan­
neer er sprake is van een ge'infecteerde brandwond, veroorzaken Gramnegatieve bacte­
rien grotere problemen dan Grampositieve. Hoe levende bacterien in een partiele dikte 
brandwond het aangeboren immuunsysteem bemvloeden is niet duidelijk. Daarom is het 
doel van het onderzoek in dit proefschrift het bestuderen van de interactie tussen delen 
van het aangeboren immuunsysteem en gramnegatieve bacterien in een muizenmodel 
van brandwonden van partiele dikte. Daarnaast werd de rol onderzocht die Lipopolysac­
charide binding protein (LBP) hierbij speelt en een potentieel nieuwe methoden om infec­
ties van brandwonden met Gramnegatieve bacterien te beheersen. 
LBP wordt gezien als een sleutelprote'ine om invasieve Gramnegatieve bacterien tegen 
te werken en een immuunreactie van de gastheer te initialiseren. Dit werd eerder ook 
bij bacteriele peritonitis beschreven. Wij waren gemteresseerd in locale en systemische 
immuunreacties op Gramnegatieve bacterien, en gebruikten hiervoor multiresistente 
Pseudomonas aeruginosa bacterien die lipopolysaccharide (LPS) in de wond brengen. Men 
denkt dat de resulterende LPS-LPB verbinding, die gemedieerd wordt door meerdere ei­
witten zoals membraangebonden en vrij voorkomende CD14 en Toll-like receptoren, de 
productie van pro- en anti-inflammatorische cytokines initieert en daarmee de afweer­
reactie van de gastheer verandert. Door de beschikking te hebben over LBP-knock-out 
muizen hadden wij een unieke mogelijkheid meer inzicht te krijgen in de reactie op LPS 
van het aangeboren immuunsysteem dat geen capaciteit tot LBP-productie heeft, met en 
zonder gestandaardiseerde infectie. 
Daarnaast gebruikten we een adenovirale construct coderend voor LBP waarmee we 
genoverdrachtstudies uitvoerden om het effect van LBP-herstel in LBP-knockout (LBPko) 
muizen en over-expressie in normale, wild-type muizen (wt) te bestuderen. Hiermee kon­
den wij het potentieel van LBP voor gentherapie en eventuele toekomstige applicaties 
voor brandwondbehandeling verhelderen. 
Kort geleden werd beschreven dat antimicrobiele peptiden een cruciale, maar slecht 
begrepen en soms wat tegenstrijdige rol in het aangeboren immuunsysteem kunnen 
spelen. Deze peptiden worden gewoonlijk volgens een "supply-and-demand" situatie ge­
produceerd door een organisme dat lijdt aan een infectie of ontsteking. Aangezien deze 
peptiden een nieuwe klasse van antimicrobiele middelen vertegenwoordigen die bac­
terien aan hun buitenste celwand aanvallen, en aangezien ze een brede werking tegen 
Grampositieve en Gramnegatieve bacterien en schimmels hebben, waren wij ge'interes­
seerd om deze nieuwe en veelbelovende peptiden in ons infectiologische brandwonde­
nonderzoek te integreren. 
Vanwege de klinische problemen die met gemfecteerde brandwonden geassocieerd zijn 
en vaak tot hoge morbiditeit en mortaliteit leiden, hebben wij een aantal experimenten 
ontwikkeld om daarmee de volgende studiedoelen te onderzoeken: 
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1) Een in vivo muizenmodel ontwikkelen voor diepe, partiele dikte {IIB) brandwonden en dit toepassen op nieuwe LBP-knock-out muizen; 
2) Meer inzicht verkrijgen in de mogelijkheid van LBP om het aantal levende, multiresisten­te, Gramnegatieve bacterien in een diepe, partiele dikte (JIB) brandwond te reduceren, met speciale aandacht voor het aangeboren immuunsysteem; 
3) Een adenoviraal construct implementeren welke codeert voor LBP, en onderzoeken of dit construct potentieel voor therapeutische doeleinden in bacterieel gei"nfecteerde brandwon­den toe te passen is; 
4) De geschiktheid van een nieuwe klasse van antimicrobiele peptides {AMPs) testen en hun vermogen bepalen om het aantal aan bacterien te reduceren binnen het model van de diepe, partiele dikte brandwond. Allereerst moest er een in vivo brandwondenmodel ontwikkeld warden, dat het ontwik­kelen en uitvoeren van de vervolgexperimenten mogelijk maakte, met als doel meer inzicht in complexe, immunologische mechanismen van geYnfecteerde, type IIB brand­wonden toe te laten. Ons eerste doel was het vermogen te vergelijken van de LBP-knockoutmuizen ten opzich­te van de normale muizen om zich te verdedigen tegen gestandaardiseerde Gramnega­tieve infecties te bestuderen. Hiervoor creeerden wij in beide muizen groepen een ges­tandaardiseerde brandwond. De wond zelf was bedoeld om een levende, herstellende wondbodem te creeren, welke klinisch als een klasse IIB brandwond gedefinieerd wordt, die de verloren dermale structuren moet herstellen. Naast de bekende desastreuze gevolgen voor patienten op brandwonden ICs, is bekend, dat IIB brandwonden tot nag slechter resultaten leiden, zodra ze ge'infecteerd raken. Omdat sommige bacterien zoals Pseudomonas aeruginosa zich in biofilmformaties kunnen verbergen en daardoor moeilijk bestreden kunnen warden, hebben wij voor een cultuur van levende, en voor al multi­resistente Pseudomonas aeruginosa bacterien voor al onze experimenten gekozen. Pseu­domonas aeruginosa blijft een van de meest problematische bacterien in de behandeling van brandwonden. In hoofdstuk 2 hebben we het ontwerp van onze experimentele set-up beschreven, bestaand uit de muizenkolonien en de gestandaardiseerde gramnegatieve brandwon­deninfecties. Allereerst waren wij ge'interesseerd of er verschillen in groei van Pseudo­monas bestonden tussen beide muizengroepen. Deze bleek er niet te zijn. Om te kun­nen bestuderen of over-expressie van LBP in normale of LBPko muizen een rol speelt in het aangeboren immuunsysteem, hebben wij een adenovirus ontwikkeld dat co-
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deert voor LBP. We konden aantonen dat het LBP-virus in vitro in staat was om IBP­
protei:neproductie te induceren. Het immunohistochemische onderzoek van een vi­
raal b-gal-kleurend controleconstruct toegediend in de huid van controle muizen liet 
vervolgens de uitvoerbaarheid van in vivo adenovirale transgen-expressie van ans 
systeem zien. Door LBP intradermaal te herstellen bij LBP-deficiente muizen en door 
over-expressie bij, normale, of wild-type muizen, werd onze hypothese bevestigd dat 
dit protei:ne belangrijk is bij Gramnegatieve infecties. Het herstel van IBP in IBP-defi­
ciente muizen leidde tot een 44-voudige reductie van het aantal Pseudomonas bacte­
rien, en door middel van over-expressie bij wild type muizen, tot een 4,9-voudige re­
ductie. Bovendien konden wij aantonen dat adenovirale gentherapie in een model van 
een gei:nfecteerde, partiele dikte brandwond bij kleine knaagdieren in vivo mogelijk is. 
In hoofdstuk 3, focusten we in meer detail op de intradermale veranderingen van muizen 
die geen LBP-proteme kunnen produceren. Wij waren vooral gei:nteresseerd in de tran­
scriptionele veranderingen die in de wand plaats vinden, en daarom vergeleken wij intra­
dermale genexpressieprofielen middels micro-array technologie na het toebrengen van 
brandwonden in beide muizengroepen. Vergeleken met wild type muizen kwamen 1802 
genen in de knockout muizen tenminste twee keer hoger dan wel lager tot expressie. 
Het gen dat het hoogst tot expressie kwam in knockout muizen was growth-related-on­
cogene-1 (GRO-1}, een CXC-chemokine dat bekend staat om het vermogen neutrofielen in 
knaagdieren aan te trekken. Neutrofielen zijn sleutelcellen in het reguleren van een im­
muunreactie. Binnen ons model kwam GRO-1 intradermaal 6 uur na het aanbrengen van 
de brandwond in LBP-knockout muizen 53-keer hoger tot expressie. Naast deze verand­
ering in het neutrofielen chemoattractant gen GRO-1, waren veranderingen van pro- en 
anti-inflammatoire cytokines voor ons van belang. Tevens voerden we een kwantitatieve 
analyse uit van perifere leukocyten en hun subsets in niet verwonde IBP-knockout mui­
zen versus de normale muizen. Deze analyse liet geen significante verschillen zien in 
beide groepen voor wat betreft het totaal aantal perifere witte bloedcellen. Vervolgens 
herhaalden we dit experiment 24 uur nadat in beide groepen een IIB brandwond aange­
bracht was. In IBP-knockouts was het totale aantal perifere leukocyten en het aantal 
neutrofielen en lymfocyten 24 uur na het trauma significant verhoogd, vergeleken met 
de niet verwonde LBPko muizen. Normale muizen lieten daarentegen geen verschil van 
beide tijdstippen in perifere leukocyten, neutrofielen en lymfocyten zien. Wel kon een 
verschil in monocyten aantallen gezien warden, die 24 uur na type IIB brandwond sig­
nificant verhoogd waren vergeleken met de niet gewonde toestand. Daarnaast wilden wij 
weten wat de expressie was van GRO-1 tesamen met andere pro- en anti-inflammatoire 
cytokines 24 uur na het induceren van de brandwond. Dit hebben we geanalyseerd door 
middel van kwantitatieve reverse-transcription polymerase chain-reaction (qRT-PCR}. Op dit 
latere moment kwam GRO-1 in de huid van knockout muizen minder sterk tot uitdruk-
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king dan in de huid van wild type muizen. Daarentegen waren de bestudeerde cytokines 
IL-6, TNFa en IL-10 op 24 uur niet significant verschillend in beide groepen. 
Om nag meer inzicht in de rol van neutrofielen in deze processen te krijgen, en de ve­
randeringen in de gen-expressieprofielen beschreven in hoofdstuk 3 te kunnen vervol­
gen, verlengden we de tijd van onze studie naar eel- en cytokinegedrag naar 96 uur 
(hoofdstuk 4). Van de bestudeerde cytokines lieten GRO-1, TNFa en IL-10 een bifasische 
expressie zien in beide diergroepen: een toename 24 uur na trauma vergeleken met 6 uur 
na trauma, een afname na 48 uur en een tweede toename na 96 uur. IL-6 daarentegen 
liet een rnonofasisch verloop zien, waarbij we bijna 10 keer minder expressie in knockout 
muizen vonden op de latere tijdstippen. TNFa en IL-10 lieten geen significante verschillen 
zien tussen de twee rnuizengroepen. Om een mogelijke relatie tussen GRO-1-regulatie 
en neutrofielengedrag in onze experimentele setting te vinden, bestudeerden we neu­
trofielen zowel intradermaal en in het perifere bloed. Perifere neutrofielenaantallen ve­
randerden niet tussen 24 en 96 uur na het trauma in LBP-knockout muizen ten opzicht 
van de normale, wild-type muizen. De normale muizen lieten een verhoging zien na 48 
uur. Zesennegentig uur na het optreden van de brandwond, hadden LBPko muizen hun 
totale aantal witte bloedcellen bijna verdubbeld, en was er sprake van een lymfocytose, 
terwijl knockout muizen een afnarne van monocyten toonden 48 uur na het letsel. Om de 
neutrofielenverdeling in de huid te kunnen bestuderen, voerden we een myeloperoxidase 
(MPO) assay uit 24, 48 en 96 uur na verwonding. Elk tijdstip liet hogere MPO spiegels 
zien in de huid van normale muizen, wat suggereert dat zich een hoger aantal, of sterker 
geactiveerde, neutrofielenpopulatie in deze groep bevindt. Het aantal neutrofielen of hun 
intradermale activatie kon niet met de eerder gevonden, intradermale GRO-1 expressie 
kinetiek gerelateerd warden. 
Omdat LBP belangrijk bleek te zijn voor gecontroleerde bacteriele infecties binnen ons 
model, waren wij ge'interesseerd in de natuurlijke bacteriele kolonisatie van herstellende 
huid met een type IIB brandwond. Hiervoor hebben we in knockout- en normale muizen 
de brandwonden onbedekt gelaten, dus zonder occlusief verband, en er werd geen ge­
controleerde bacteriele infectie ge'induceerd. Zes dagen na het trauma, vonden we meer 
bacterien op de huid van normale rnuizen dan op die van knockout muizen. Deze kolonies 
waren voornamelijk Grampositief. Gebrek aan LBP verandert blijkbaar de lokale afweer­
capaciteit van een organisme tegen infecties die in een brandwond ontstaan. Daaruit 
kunnen we concluderen, dat er mogelijk een immunologisch, compenserend mechanisme 
bestaat, welke in staat is om de afwezigheid van LBP ten minste te compenseren. 
Gezien de toenemende problematiek van multidrug resistente bacterien, heeft een oud 
deel van het aangeboren immuunsysteem de laatste 10 tot 15 jaar meer en meer aan­
dacht gekregen. Antirnicrobiele peptiden (AMPs) komen bij planten, koudbloedige dieren 
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en vertebraten en ook bij mensen voor. Hun potentiele nut voor de kliniek was onder­
werp van ons onderzoek beschreven in hoofd.stuk 5. AMPs zijn oude verdedigingsmid­
delen, die door infecties en ontstekingen getriggerd worden. Deze kleine peptiden vallen 
binnendringende bacterien, virussen en schimmels aan, wanneer deze bekleed zijn met 
lipide-lagen aan hun buitenste celwand. AMPs spelen dus een cruciale rol in het aange­
boren immuunsysteem. Onze hypothese was, dat dit soort peptiden van nut waren voor 
de behandeling van brandwondgerelateerde infecties. Om dit te testen, hebben we een 
antimicrobieel peptide ter grootte van 18 aminozuren laten maken wat Protegrin-1 (PG-1) 
wordt genoemd. De in vitro effectiviteit werd eerst door middel van een radiale diffusie 
analyse tegen Pseudomonas aeruginosa getest. We konden aantonen, dat het bacterio­
toxisch effect concentratie-afhankelijk was en dat dit effect niet verloren ging, zodra we 
het peptide met een commercieel te verkrijgen fibrinelijm mengden. De noodzaak om 
de twee componenten te mengen kwam voort uit praktische problemen: het opgeloste 
bioactieve peptide had een waterachtige consistentie en druppelde simpelweg van de 
brandwond af, zonder lang genoeg in situ te blijven om het antibacteriele effect uit te 
oefenen. Vervolgens pasten wij dit peptide toe in in vivo studies, binnen het gestan­
daardiseerde, ge'infecteerde brandwondmodel. We konden hier een substantiele reductie 
van Pseudomonas bacterien in de brandwonden mee bewerkstelligen. 
Samenvattend hebben we een muizenbrandwondenmodel van een diepte 11B ontwik­
keld, en dit vervolgens op een muizenkolonie toegepast, die geen mogelijkheid had tot 
productie van LBP, wat als belangrijk voor het afweren van Gramnegatieve infecties word 
gezien. Met dit model konden wij aantonen, dat afwezigheid van LBP in knockout mui­
zen per se een adequate immuunreactie in een ge'infecteerde brandwond niet in de weg 
staat. Een adenovirale construct welke LBP codeert, was in staat brandwond gerelateerde 
Pseudomonas aeruginosa bacterie-groei in knockout- en normale muizen significant te 
reduceren. Intradermale genexpressie analyse liet substantieel verschillende pro- en anti­
inflammatoire cytokine-expressieprofielen zien op verschillende tijdpunten na aanbren­
gen van de brandwond in aan- respectievelijk afwezigheid van LBP prote'ine. Het intra­
dermale chemokine GR0-1 werd op een vroeg tijdstip na trauma in LBP-knockout muizen 
tot overexpressie gebracht. Omdat GR0-1 een belangrijke factor voor het aantrekken 
van neutrofielen wordt gezien, bestudeerden we leukocyten en leukocyten-subsets in bet 
perifere bloed, en vonden verschillende cellulaire immuunreacties van muizen die geen 
LBP konden maken in reactie op de gestandaardiseerde, partiele dikte brandwond. Er 
worden niet meer neutrofielen of verhoogde neutrofielen-activiteit - systemisch of lokaal 
- in dit brandwondmodel van knockout muizen gevonden. In knockout muizen werden 
lokaal minder bacterien gezien als ze een natuurlijke dermale rekolonisatie van 6 dagen 
post-trauma ondergingen, deze waren voornamelijk Grampositief. Wij concludeerden, 
dat er in het geval van afwezigheid van LBP mogelijk een compensatoir immunologisch 
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mechanisme bestaat. Door het toepassen van Protegrine-1 ,  een voorbeeld antimicrobieel 
peptide, in een mengsel met fibrine-lijm, konden wij een reductie van Pseudomonas aeru­
ginosa bacterien binnen een type IIB brandwond aantonen. Dit is een potentieel nieuwe 
behandeling van ge'infecteerde brandwonden. 
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N.Mahomed, N.McKnee, P.Solomon, L.U.Lahoda, A.E.Gross; JBJS (B), 1994, 76-B, 88-90 
2} The use of tissue expanders in the revision of a lmee fusion to a total lmee arthro­
plasty; Solomon P.R.,Lahoda L.U.,Mahomed N., Gross A.E.; University of Toronto, 
Medical Journal, Vol.70 No.1, 1992 
4) Vergleich der parallel und divergent augmentierten Rekonstruktionen des vorderen 
Kreuzbandes; Lahoda LU, Wiener Klin. Wochenschrift 105(19):558-559, 1993 
5) Scapulothorakale Dissoziation, Ein missed injury?; Lahoda LU, Kreklau B, Gekle C, 
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Gupta K, Lahoda LU, Boorboor P, Vogt PM, Chirurg. 2004 Mar;75(3):257-64 
18) The free ,,mutton chop" flap: a fascio-musculocutaneous flap for the reconstruction 
of the entire sacral and perineal area; Vogt PM, Kall S, Lahoda LU, Spies M, Muehlber­
ger T; Plast Reconstr Surg. 2004 Oct;l 14(5):1220-4 
19) Use of soleus muscle flaps for coverage of distal third tibial defects; Kauffman CA, 
Lahoda LU, Cedema PS, Kuyon WM; J Reconstr. Microsurg., 2004 Nov 20(8): 593-7 
21) Plasma concentration of edothelin-1 after myocutaneous latissimus-dorsi-transplan­
tation, role in reperfusion injury; Jokuszies A, Jansen v, Lahoda LU, Steinau HU, Vogt 
PM; Hand Mikro Plastische Chirurgie, 2005 (6), 37(3), 193-201 
22) Gestielte Lappenplastiken fiir Schadelkalotte, Orbita, Sakrum und Kniebereich; PM 
Vogt, T Peters, P Brachvogel, E Rickels, LU Lahoda, A Jokuszies, M Spiel?,, Handchir 
Mikrochir Plast Chir 2005; 37 
24} Breast cancer - plastic surgical strategies for the treatment of tumor infiltration of 
the thoracic wall and brachial plexus; Vogt PM, Busch K, Spies M, Lahoda LU, Kall S, 
Klima U, Jokuszies A, Zentralbl Gynakol 2005 (12) 127 (6): 407-11 
25) Influence of transendothelial mechanisms on microcirculation: consequences for 
reperfusion injury after free flap transfer. Previous, current, and future aspects. Re­
view.; Jokuszies A, Niederbichler A, Meyer-Marcotty M, Lahoda LU, Reimers K, Vogt 
PM. J Reconstr Microsurg. 2006 Oct;22(7):513-8. 
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PM. Chirurg. 2006 Dec;77(12):1144-1151. 
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burn wounds; Lahoda LU, Wang SC, Vogt PM. Chirurg. 2006 Mar;77(3):251-6 
28) Letter to the editor. Scaphoidfrakturen beim Sportier; Knobloch K, Lahoda LU, Heck­
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mas of the upper limb; Vogt PM, Lahoda LU, Spies M, J Plast Reconstr Aesthet Surg, 
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31) Fully 3-dimensional digitally planned reconstruction of a mandible with a free vas­
cularized fibula and immediate placement of an implant-supported prosthetic cons­
truction; Schepers RH, Raghoebar GM, Vissink A, Lahoda LU, Van der Meer WJ, Roo­
denburg JL, Reintsema H, Witjes MJ. Head Neck. 2011 Oct 24. [Epub ahead of print] 
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Springer 2004; Kapitel: Plastisch-chirurgische Behandlung von Weichteildefekten, 
S. 76 (Vogt, Lahoda, Kall, DasGupta) 
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gie: Nekrotisierende Fasziitis", 29.Ausgabe 2004, Kap. III-4 
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liche Begutachtung" Ludolph/ Lehmann /Schiirmann, EcoMed, 8.Ausgabe 12/07, VI-
1.3.11, 2007 
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31, S.271 "Gutartige Tumoren der Haut, inklusive Navi" 
8) Lahoda LU, in Vogt PM: ,,Praxis der Plastischen Chirurgie", Springer Verlag 2011 
Kap.32, S.279 ,,Maligne Tumoren" 
9) Lahoda LU, in Vogt PM:"Praxis der Plastischen Chirurgie", Springer Verlag 2011 
Kap.33, S.289 ,,Strahlenfolgen" 
10) Lahoda LU, in Vogt PM:,,Praxis der Plastischen Chirurgie", Springer Verlag 2011 
Kap.84, S.811 ,,Fehlbildungen der Fiisse" 
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Dr.Lars-Uwe Lahoda was born on Feb 18th 1968 in Zell am See, Salzburg, Austria. He 
studied medicine in Vienna, where he submitted his doctoral thesis on anterior crud­
ate ligament reconstruction and the effect of 'through the condyle versus over-the top 
augmentation', with Prof.Dr.R.Schabus being his doctoral father. In 1993, he was a for­
eign medical student at Mount Sinai Hospitals (orthopedic surgery, Prof.Dr.Allan E Gross), 
University of Toronto, Canada. On June 3rd 1993 he graduated as a medical doctor at the 
University of Vienna, after having been awarded a performance scholarship by the Aus­
trian Government during the last year of his studies. 
A few weeks later, he began his residency at the general hospital of Zell am See and com­
pleted basic medical training (surgery, traumatology, internal medicine, ENT, pediatrics, 
neurology and gynecology), before he applied for a scholarship, granted by the Austrian 
Government enabling a 6 months stay in New York as a foreign medical resident at the or­
thopedic department of Columbia Presbyterian Medical Center, NYU (Chair Prof.Dr.Louis 
U. Bigliani). In Austria he completed his advanced trauma life support (ATIS) training in 
1995 to become a certified emergency physician. Dr.Lahoda applied for a residency train­
ing program in surgical traumatology in Bochum, Germany after having returned to Eu­
rope in 1996 and received his specialty in surgery, emphasis on orthopedic traumatology 
with Prof.Dr.Gert Muhr in 2000. He spent several years training in intensive care as well 
as rotating half a year with Prof.Dr.Ulrich Steinau, head of the plastic surgical depart­
ment and bum unit at the "Bergmannsheil", University of Bochum's trauma hospital. 
After having worked for one year as a board certified surgeon at "Bergmannsheil", he ap­
plied for an research fellowship (NIH grant) at the Trauma Bum Center of the University 
of Ann Arbor, Michigan, at Prof.Dr. Stewart Wang ,  s lab, conducting the research being 
the subject of this thesis. He also spent time with the plastic surgical department at the 
University of Michigan, (head: Prof.Dr.William Kuzon). During the time in Ann Arbor, 
Dr. Lars-Uwe Lahoda was participating in the National Car Crash Investigation Program 
(CIREN). In 2003 he returned to Germany and completed his training in plastic surgery 
at the University of Hannover (head: Prof.Dr.Peter Vogt), covering every aspect of plastic, 
hand and reconstructive surgery and bums. He became staff in 2004, passed the boards 
as a certified plastic, hand and reconstructive surgeon in 2006, had his German doctoral 
degree officially accredited by the University of Hannover in the same year, and passed 
the boards for hand surgery in 2008. 
Since April 2008 Dr.Lahoda works as staff member and consultant at the University of 
Groningen, the Netherlands (Prof.Dr.Paul Werker) and acted as Chief of Clinic for two 
years. In 2009 he was invited as visiting professor at the Plastic Surgical Department in 
Ann Arbor, Ml. 
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Addendum 3 Dr.Lahoda , s professional interest lies in reconstructive surgery, traumatology, hand sur­gery, microsurgery, hand and neck reconstructions and intensive care medicine as well as breast reconstructions. His research interest lies in immunology, especially wound infec­tions, furthermore in foreign body reactions associated with surface-modifications and alterations regarding ingrowth. He is a reviewer for 3 medical journals, has published journal articles and book-chapters, and has given more than 60 presentations world­wide. Dr.Lahoda has been and is an invited speaker at specialist , s meetings and holds currently full membership in 11 medical professional societies in Austria, Germany, the Netherlands and the USA. He is a board member of the International Confederation for Plastic, Reconstructive and Aesthetic Surgery (IPRAS) and is the European liaison of the Plastic Surgical Research Council (PSRC). 
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As possibly true for everyone else who successfully completed his/her PhD-thesis, this 
work represents the result of 'blood, sweat'n tears'. All in all, more than 10 years of 
my life including the 2 research years in Michigan have been put together in this very 
booklet. When I left Germany in 2001 for Ann Arbor, next to quitting my job in Bochum, 
I also left behind 'my' world of trauma surgery and intensive care medicine which had 
determined me and had caught my focus for so many years. 
I did not know what the future might bring at the time, nor where it might possibly be. 
My medical world had turned upside down. Shortly after starting my research, facing the 
challenge of a cutting edge lab, the Twin Towers in New York fell, a city I knew and lived 
in. This proud and strong country turned into chaos right before my eyes. I remember 
details of this day very clearly . . .  June had called and made us aware of the fact that 
'America was under attack' as she put it and we therefore had to 'postpone our dinner' 
that night. Sandra and I had no idea what had happened, since we neither had TV nor 
radio as we only were in the country for a short time. Even today, whenever there are 
television programs or documentaries reporting on '9-11 ', my throat tightens. Therefore, 
this period of my life stands for lots of changes and personal events, keeping my memory 
fresh. I am proud to have been (and still am) a member of the 'Michigan family' as Bill Ku­
zon once put it. In Ann Arbor I met outstanding people, saw researchers work and think 
in spheres 'beyond my comprehension', and even gotten in touch with colleagues who 
until today, admirably compete on the highest clinical and scientific levels, as represented 
for instance at PSRC or SIS-A meetings. Next to the job, there was little time for a private 
life. We have attended June and Matt's wedding, Geine and John's, have even been wit­
nesses to Hanka and Richard's and made great friends with Sandy and Graham, as well 
as Anu and Rinki, and Lisa. Also, we organized a 'stretch-limo' tour for my dad who had 
turned 60, saw Ptizer move headquarters to Ann Arbor with great impact on the city, rode 
to Domino's Farm a few times, and finally . . .  I decided to skip traumatology in favor of 
plastic surgery when the decision was made to return to Europe. This should only give 
a glimpse of what was going on at the time, but until today, mentioned yet again, it still 
has an impact on me. But, this is the place meant to thank people who have helped, ac­
companied and contributed. 
First and foremost I want to thank my parents. Not only during my time in Michigan, 
but of course throughout my life, my parents have supported me in every thinkable way, 
positively criticized and stimulated me and my thoughts and served as 'good spirits' in 
so many ups and downs. They were and always are there when needed, they make me 
feel save and 'home'. They are the best people to share thoughts with and whose opinion 
I reflect and appreciate enormously. Without them I wouldn , t be who I am and where I 
am today. Vielen, vielen Dank! 
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Starting at the very beginning of my career, I would like to thank all of my 'mentors' even 
though some might not be aware to be serving as such. Rudi Schabus, for taking me as a 
'doctorate candidate' at the end of my studies in Vienna, canalizing and stimulating my 
interest in sports injuries, especially knees. Hadn , t I had my first meeting with Rudi, the 
trauma surgeon at the University of Vienna 1 hour before meeting with Prof.Meiss!, the 
plastic surgeon discussing the same subject, my career would surely have been totally 
different. 
I ,  d like to thank the University of Vienna and Austrian Government for granting me 
a 'gifted scholarship' during my studies as well as 2 stipends enabling me to: 1) go to 
Toronto at the end of my studies (Allan E Gross, Orthopedics at Mount Sinai) and 2) to 
reside in New York for 6 months spending half a year on the very impressive shoulder sur­
gery program led by Louis Bigliani at NYU, Columbia Presbyterian Hospital. Rudi, Herbert 
Resch (Salzburg, Austria), Allan Gross and Louis Bigliani need to be gratefully mentioned 
as they initiated my 'kicking off' and therefore left their footprints. 
My first 'real' job in 1993 when I started as a resident has taught me invaluable treasures: 
thinking of WHAT to do WHEN and that medicine is no walk in the park. I started off in 
the hospital of Zell am See, my home. Being thrown into the water you sink or swim. 
In order to get accepted for training, I needed to start working without salary for an 
unknown period of time in order to proof my ambition to become a resident. Finally, I 
got accepted and joined their rotational program for almost 3 years as part of my basic 
medical training. 
Gert Muhr in Bochum has surely made a thorough impression in my life. Both educa­
tionally and personally, I am amazed by how a single person managed to have such an 
impact. At the current stage of my career I understand his thoughts much better he used 
to share in short, unforgotten, sometimes 'snappy' statements and I am proud to have 
trained in his institution. He has left a 'mark on my forehead', even though I don , t do 
traumatology anymore and it would be a lie not to admit, that I every now and then miss 
it, since I learned so much. Lots of friendships date back to these 5 years, I recall numer­
ous unforgettable situations, both personal and professional. 
I am also very grateful to have worked with Peter Vogt who I met while in Bochum and 
who introduced me to plastic surgery. I was extremely impressed by Uli Steinau, Detlev 
Hebebrand and Frank Peter and of course Peter himself. Since then I regarded plastic, 
especially reconstructive surgery including hands, as a logic, advancing step forward, 
based on my previous training. Peter has influenced me personally as well as profession­
ally a lot. He once put it that way: ' . . .  do you realize that you are standing on the shoul­
ders of giants .. ?' meaning Uli Steinau and Gert Muhr. After having returned from the US, 
I gladly joined his service in Hannover, which he had just taken over and begun to build. 
When thinking of the time 2001 to 2003 in the Trauma Bum lab of UoflvI Ann Arbor, Mich­
igan, I would like to thank my PI Stewart Wang, Grace Su, Mark Hemmila, Sam Arbabi, 
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Acknowledgments Mark Sochor (as old, new family), Mita Ghosh, Jianmin Sun, Nancy Gong, Aladdein Mat­tar, Ali Amenlari, Richard Klein, as well as Sandy Lemkin, Carla Kohoyda-Inglis and Sybil Boone, the Remick lab and all members of UMPIRE/CIREN. Also, the 'Michigan family of plastic surgeons', my friends Bill Kuzon (a real role model) and Paul Cederna (congrats! ,  my greatest respect!), who are absolute powerhouses both personally and professionally. It is now that I realize what 'Michigan family' means and how lucky I am to be affiliated, how honored and extremely privileged I am to know them and have seen them work, seen them conduct research and approach problems. Stewart as my PI enabled me to dive into basic science and research on a high level, representing the backbone of this booklet, for which I am grateful. Groningen, the Netherlands, Paul Werker and his team have offered a new home. Thanks to them, I picked up a new language, made new friends, faced new challenges and learned many things, in short: I progressed, for which I am again very thankful! People in the North of the Netherlands are straightforward, a handshake means contract and the way they are reminds me of my Austrian home, mixed with international experience, not bad! I would like to thank Paul, who observes carefully, critically, balances distance and close­ness and most of all, tries to positively stimulate and offers support. Paul agreed to let me write this booklet (saying for instance one word: . . .  'focus' . . .  ), which means - in regards of what I wrote about my past- simply a lot to me, and offers dosing a long, sometimes painful but also wonderful and somewhat turbulent book chapter. Thank you, Paul. Ingrid Molema deserves my very special thanks, since without her and her constant 'quest for improvement' this would surely not have been possible at all. Ingrid has a gift: encouraging people to literally give their best, push to their boundaries and limits and therefore show the best of what one can do. This really means a great deal to me, since it has helped opening up my eyes, understanding and thinking like 'real' researchers and being very, very analytical. Every tiny little step along the way, I had to admit to myself that Ingrid ' s  points were very well made, generated by careful analysis, respectful and most of all: resulted in improvement in so many ways. Thank you so much, with my deep­est respect and acknowledgment I have to say: it has been a privilege for me! I would like to thank everyone at the University of Groningen, my fellow staff colleagues, all of our AIOSsen / residents (keep up the great work and most of all: stay curious! there is so much to learn, thank you for the privilege of working with you and sharing my knowledge with you), students who start their research work in our department, the supporting people of the department, everyone on the ward, the outpatient clinic, people I collaborate with as a plastic, reconstructive surgeon and everyone who has helped directly or indirectly in the completion of this booklet. I am also very grateful to the com­mission (Professors Loe de Leij, Henny van der Mei and Paul van Zuijlen) on positively judging this work. 
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Addendum 4 I am very grateful to be able to learn continuously, a lot, from lots of people. Hardly ever, I have to admit, am I satisfied with second best in professional terms, which I expect from myself and I realize that this might sometimes be hard to understand. My ethical attitude comes from several different influences, too many and too personal to be mentioned here, they know who they are and they know I shall always be bound to them. Through my rather 'twisty' and somewhat unusual education, including jobs in 5 different coun­tries, I have gotten insights into thought processes and strategies of dealing with each other which opened up my mind, ever since living in an international students hostel, the Albert-Schweitzer-Haus in Vienna. I consider myself as 'curious' and my task to help and serve those needing medical attention, with the little I know and the little I can do. Along my way, there are numerous personal friends, family and relations who have sup­ported, influenced and changed me to what I am today, all of whom deserve my deepest appreciation and thanks. My old friends Alex, Christian, Megan, Ruth, Karin, Yvi, Mirjam Neumann and Dietmar have supported me, shared time and joy and sometimes sad mo­ments, thank you all for being there when needed! Also, my 'new friends' Harald, Sandy and Graham, Richard and Hanka, Susan and Erik, thanks for your support and wonderful friendship! Marieke and Charmaine: both of you are much more than 'just my paranimfs' to me, as you know. It is great that within such a short time, we have become such great friends, are taking part in each other's lives and truly are some 'soul mates'. Thanks for your help, understanding and support, all the Port wine, the cooking, the 'gezelligheid', the hours at Minnar's, the great food, your Maltese and international spirits and 'het Nederlands meisje' in jou, Marieke. Great to dream together, build futures and rehearse, think, create and reflect. Love you all (including George of course! ! ! ). Last but not least! !  To all my friends: thank you for being around when needed, thank you for being such great friends who I don ' t  see as much as I actually want to since you are spread all over the world, thank you for enabling me to continue chatting, contemplating and having fun right where we had left the last time, 'as if there was no time in-between' and thank you for being a part of me. 144 
